<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0217390</article-id>
<article-id pub-id-type="publisher-id">PONE-D-18-22335</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Heredity</subject><subj-group><subject>Genetic mapping</subject><subj-group><subject>Variant genotypes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Metaanalysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Metaanalysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Computational biology</subject><subj-group><subject>Genome analysis</subject><subj-group><subject>Genome-wide association studies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject><subj-group><subject>Genome analysis</subject><subj-group><subject>Genome-wide association studies</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Human genetics</subject><subj-group><subject>Genome-wide association studies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genetic loci</subject><subj-group><subject>Alleles</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Behavior</subject><subj-group><subject>Recreation</subject><subj-group><subject>Sports</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Behavior</subject><subj-group><subject>Recreation</subject><subj-group><subject>Sports</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Sports science</subject><subj-group><subject>Sports</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Behavior</subject><subj-group><subject>Human performance</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Behavior</subject><subj-group><subject>Human performance</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Science policy</subject><subj-group><subject>Research integrity</subject><subj-group><subject>Publication ethics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Biological locomotion</subject><subj-group><subject>Running</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Biological locomotion</subject><subj-group><subject>Running</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Association of the <italic>ACTN3</italic> R577X (rs1815739) polymorphism with elite power sports: A meta-analysis</article-title>
<alt-title alt-title-type="running-head">Meta-analysis <italic>ACTN3</italic> polymorphism elite power sports</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-4191-2802</contrib-id>
<name name-style="western">
<surname>Tharabenjasin</surname>
<given-names>Phuntila</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Pabalan</surname>
<given-names>Noel</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-8652-2560</contrib-id>
<name name-style="western">
<surname>Jarjanazi</surname>
<given-names>Hamdi</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Chulabhorn International College of Medicine, Thammasat University, PathumThani, Thailand</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Environmental Monitoring and Reporting Branch, Ontario Ministry of the Environment, Conservation and Parks, Toronto, Ontario, Canada</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Lammi</surname>
<given-names>Mikko Juhani</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Umeå, SWEDEN</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">noelpabalan@mail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>14</volume>
<issue>5</issue>
<elocation-id>e0217390</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>5</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Tharabenjasin et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0217390"/>
<abstract>
<sec id="sec001">
<title>Objective</title>
<p>The special status accorded to elite athletes stems from their uncommon genetic potential to excel in world-class power sports (PS). Genetic polymorphisms have been reported to influence elite PS status. Reports of associations between the <italic>α-actinin-3</italic> gene (<italic>ACTN3</italic>) R577X polymorphism and PS have been inconsistent. In light of new published studies, we perform a meta-analysis to further explore the roles of this polymorphism in PS performance among elite athletes.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>Multi-database literature search yielded 44 studies from 38 articles. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were used in estimating associations (significance threshold was set at P<sup>a</sup> ≤ 0.05) using the allele-genotype model (R and X alleles, RX genotype). Outlier analysis was used to examine its impact on association and heterogeneity outcomes. Subgroup analysis was race (Western and Asian) and gender (male/female)-based. Interaction tests were applied to differential outcomes between the subgroups, P-values of which were Bonferroni corrected (P<sub>interaction BC</sub>). Tests for sensitivity and publication bias were performed.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>Significant overall R allele effects (OR 1.21, 95% CI 1.07–1.37, P<sup>a</sup> = 0.002) were confirmed in the Western subgroup (OR 1.11, 95% CI 1.01–1.22, P<sup>a</sup> = 0.02) and with outlier treatment (ORs 1.12–1.20, 95% CIs 1.02–1.30, P<sup>a</sup> &lt; 10<sup>−5</sup>–0.01). This treatment resulted in acquired significance of the RX effect in Asian athletes (OR 1.91, 95% CI 1.25–2.92, P<sup>a</sup> = 0.003). Gender analysis dichotomized the RX genotype and R allele effects as significantly higher in male (OR 1.14, 95% CI 1.02–1.28, P<sup>a</sup> = 0.02) and female (OR 1.58, 95% CI 1.21–2.06, P<sup>a</sup> = 0.0009) athletes, respectively, when compared with controls. Significant R female association was improved with a test of interaction (P<sub>interaction BC</sub> = 0.03). The overall, Asian and female outcomes were robust. The R allele results were more robust than the RX genotype outcomes. No evidence of publication bias was found.</p>
</sec>
<sec id="sec004">
<title>Conclusions</title>
<p>In this meta-analysis, we present clear associations between the R allele/RX genotype in the <italic>ACTN3</italic> polymorphism and elite power athlete status. Significant effects of the R allele (overall analysis, Western and female subgroups) and RX genotype (Asians and males) were for the most part, results of outlier treatment. Interaction analysis improved the female outcome. These robust findings were free of publication bias.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>The author(s) received no specific funding for this work.</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="6"/>
<page-count count="20"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>Exceptional performance during national/international-level competitions defines elite athletes [<xref ref-type="bibr" rid="pone.0217390.ref001">1</xref>]. Among elite power sports (PS) athletes, performance varies across countries, races and gender. This variation stems from genetic and environmental factors. It has been reported that genes play a substantial role in muscle function, specifically those involving the PS phenotype [<xref ref-type="bibr" rid="pone.0217390.ref002">2</xref>,<xref ref-type="bibr" rid="pone.0217390.ref003">3</xref>]. Genetic variants (i.e. polymorphisms) are vital in understanding the potential influence of genes on PS [<xref ref-type="bibr" rid="pone.0217390.ref004">4</xref>] but published outcomes have been variable [<xref ref-type="bibr" rid="pone.0217390.ref005">5</xref>,<xref ref-type="bibr" rid="pone.0217390.ref006">6</xref>]. Nevertheless, lines of evidence have catapulted the <italic>ACTN3</italic> (<italic>α-actinin-3</italic>) polymorphism into prominence regarding its association with PS performance [<xref ref-type="bibr" rid="pone.0217390.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0217390.ref008">8</xref>].</p>
<p><italic>ACTN3</italic> is the gene that encodes for <italic>α-actinin-3</italic>, which is a sarcomeric protein expressed mainly in type II muscle fibers [<xref ref-type="bibr" rid="pone.0217390.ref009">9</xref>]. Type-II muscle fibers are involved in generating explosive and powerful muscle contractions. A common polymorphism in this gene is <italic>ACTN3</italic> R577X (rs1815739), where a cytosine-to-thymine base substitution transforms the arginine base (R) to a premature stop codon (X). The X allele is a loss-of-function variant wherein homozygosity results in a complete lack of expression of <italic>α-actinin-3</italic>, the deficiency of which occurs in ~20% of the world’s population [<xref ref-type="bibr" rid="pone.0217390.ref008">8</xref>]. Given functional de-emphasis on the X allele, greater attention has been paid to the relationship of the R allele with PS performance [<xref ref-type="bibr" rid="pone.0217390.ref010">10</xref>] where athletes with the RR genotype are associated with high muscle strength [<xref ref-type="bibr" rid="pone.0217390.ref011">11</xref>] and power [<xref ref-type="bibr" rid="pone.0217390.ref012">12</xref>]. In line with these findings, we examine the hypothesis that the RR genotype is more common among sprint/power athletes compared with their controls [<xref ref-type="bibr" rid="pone.0217390.ref004">4</xref>,<xref ref-type="bibr" rid="pone.0217390.ref013">13</xref>].</p>
<p>The popularity of <italic>ACTN3</italic> in sports performance is attested by its coverage in several reviews [<xref ref-type="bibr" rid="pone.0217390.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0217390.ref008">8</xref>,<xref ref-type="bibr" rid="pone.0217390.ref014">14</xref>,<xref ref-type="bibr" rid="pone.0217390.ref015">15</xref>]. Current knowledge regarding associations of the <italic>ACTN3</italic> R577X polymorphism with sports performance involves investigation of its polygenic nature and interactions [<xref ref-type="bibr" rid="pone.0217390.ref016">16</xref>–<xref ref-type="bibr" rid="pone.0217390.ref020">20</xref>]. Thus, <italic>ACTN3</italic> literature has focused on association analyses between several genes related to sports performance [<xref ref-type="bibr" rid="pone.0217390.ref021">21</xref>,<xref ref-type="bibr" rid="pone.0217390.ref022">22</xref>]. Genome-wide association studies (GWAS) involving <italic>ACTN3</italic> is an emerging possibility in the genomics of sports science. More commonly in <italic>ACTN3</italic> R577X research, however, is the study of the R and X alleles as well as RX genotype frequencies between athlete and control; between sport types, mainly power and endurance and comparisons between populations. Studies have found that the R allele is more frequent in power athletes than controls [<xref ref-type="bibr" rid="pone.0217390.ref023">23</xref>] and in power more than endurance [<xref ref-type="bibr" rid="pone.0217390.ref024">24</xref>]. However, other studies on PS performance showed no associations, rendering inconsistency in the outcomes [<xref ref-type="bibr" rid="pone.0217390.ref022">22</xref>,<xref ref-type="bibr" rid="pone.0217390.ref025">25</xref>,<xref ref-type="bibr" rid="pone.0217390.ref026">26</xref>].</p>
<p>Meta-analysis is a potent methodology that synthesizes the results of independent studies thus increasing statistical power and resolution. Our rationale for doing this meta-analysis rests on the following: (i) the synthetic approach gives a simultaneous overview and detailed profiles of the role of <italic>ACTN3</italic> R577X in PS performance which is facilitated by an arsenal of meta-analysis tools that can be used; (ii) primary study outcomes on this topic have been inconsistent with associations found in some reports [<xref ref-type="bibr" rid="pone.0217390.ref004">4</xref>,<xref ref-type="bibr" rid="pone.0217390.ref026">26</xref>,<xref ref-type="bibr" rid="pone.0217390.ref027">27</xref>] and none in others [<xref ref-type="bibr" rid="pone.0217390.ref028">28</xref>–<xref ref-type="bibr" rid="pone.0217390.ref030">30</xref>] and (iii) new studies have since been published. In this study, we aim to determine the role of <italic>ACTN3</italic> R577X in the PS phenotype among elite power athletes.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec007">
<title>Selection of studies</title>
<p>We searched MEDLINE using PubMed, Science Direct and Google Scholar for association studies as of June 28, 2018. The terms used were <italic>“α-actinin-3</italic>”, “<italic>ACTN3</italic>”, “elite”, “athlete”, “power sports” and “polymorphism” as medical subject headings and text, restricted to the English language. References cited in the retrieved articles were also screened manually to identify additional eligible studies. The exclusion criteria were; (i) review; (ii) subjects were non-human; (iii) non-English; (iv) studies did not involve PS performance (e.g. <italic>ACTN3</italic> polymorphism effects in disease conditions or cases were non-athletes) and (v) not <italic>ACTN3</italic> by title/abstract. Other exclusion criteria are listed in <xref ref-type="fig" rid="pone.0217390.g001">Fig 1</xref> and <xref ref-type="supplementary-material" rid="pone.0217390.s001">S1 List</xref>. The inclusion criteria were: (i) case–control study design evaluating the association between <italic>ACTN3</italic> R577X polymorphism and elite power athletes; (ii) sufficient genotype frequency data to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) and (iii) controls in studies comply with the Hardy-Weinberg Equilibrium (HWE) which was assessed using the online application (<ext-link ext-link-type="uri" xlink:href="https://ihg.gsf.de/cgi-bin/hw/hwa1.pl" xlink:type="simple">https://ihg.gsf.de/cgi-bin/hw/hwa1.pl</ext-link>). <xref ref-type="supplementary-material" rid="pone.0217390.s002">S1 Table</xref> details information about the excluded articles based non-compliance with HWE.</p>
<fig id="pone.0217390.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0217390.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Summary flow chart of literature search.</title>
<p><italic>ACTN3</italic>: <italic>alpha-actinin-3</italic>; HWE: Hardy-Weinberg Equilibrium; PS: power sports.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec008">
<title>Data extraction</title>
<p>Two investigators (PT and NP) independently extracted data and arrived at a consensus. Authors were contacted in order to obtain more information on incomplete data. The following information was extracted from each article: first author’s name, published year, country of origin, race and gender of participants, those that addressed gene-gene, gene-environment interactions, those that used haplotype analysis, matching and sample source. Reference lists of screened full-text articles were scanned for additional studies. Where articles reported multiple genotypes under PS levels, we chose those that referred to “elite” or “international” or otherwise contextualized the status of elite athletes according to Lorenz et al [<xref ref-type="bibr" rid="pone.0217390.ref031">31</xref>]. Departures of genotypic frequencies from the HWE in control subjects were determined with the χ<sup>2</sup> test.</p>
</sec>
<sec id="sec009">
<title>Quality assessment of the studies</title>
<p>The Clark-Baudouin (CB) scale was used to evaluate methodological quality of each included study [<xref ref-type="bibr" rid="pone.0217390.ref032">32</xref>]. Suitability of this scale is based on criteria that include P-values, addressing statistical power issues, corrections for multiple testing, sample size comparisons between cases and controls, use of primers and detailing of genotyping methods. CB scores range from zero (worst) to 10 (best) with low and high quality designated as &lt; 5 and ≥ 5, respectively.</p>
</sec>
<sec id="sec010">
<title>Data distribution and publication bias</title>
<p>Data distribution was assessed with the Lilliefors corrected-Kolmogorov-Smirnov (KS) test [<xref ref-type="bibr" rid="pone.0217390.ref033">33</xref>] using SPSS 20.0 (SPSS Inc., IBM Corp. Chicago, IL, USA). Descriptive statistics of normally distributed data were expressed as mean ± standard deviation (SD), otherwise, we used median and interquartile range (IQR). We assessed publication bias using WINPEPI [<xref ref-type="bibr" rid="pone.0217390.ref034">34</xref>]. Study-specific ORs were used as operating data for publication bias tests, the choice of which depended on their distribution. Inferential protocol warranted the Egger’s test [<xref ref-type="bibr" rid="pone.0217390.ref035">35</xref>] for normally distributed data, otherwise, the Begg-Mazumdar test was used [<xref ref-type="bibr" rid="pone.0217390.ref036">36</xref>].</p>
</sec>
<sec id="sec011">
<title>Data synthesis</title>
<p>We estimated associations (OR) and 95% CI among elite athletes for each study. Where genotype values were zero, we applied the Laplace correction by adding a pseudo-count of one to all values of the data set [<xref ref-type="bibr" rid="pone.0217390.ref037">37</xref>] before constructing the forest plots. Because frequency of the variant X allele was non-uniform, we compared the following: (i) X allele with RX/RR genotype; (ii) R allele with RX/XX genotype and (iii) RX genotype with homozygous RR and XX genotypes (heterozygote comparison). This modeling approach facilitates comparisons and interpretations of findings with <italic>ACTN3</italic> literature. Raw data for genotype frequencies, without adjustment, were used to calculate study-specific ORs. To assess the strength of evidence, we used the following indicators: (i) magnitudes of effects are stronger or weaker when the values are closer to or farther from the non-associative OR of 1.0, respectively; (ii) precision of effects was assessed with the confidence interval difference (CID = upper CI—lower CI). High and low CID values indicate low and high precision, respectively and (iii) P-values close to 0.05 and 0.0001 indicate moderate and high significance, respectively. Two-sided P-values of ≤ 0.05 were considered significant except in estimations of heterogeneity where the threshold was set at ≤ 0.10 on account of the low power of the χ<sup>2</sup>-based Q test [<xref ref-type="bibr" rid="pone.0217390.ref038">38</xref>]. Heterogeneity between studies was estimated with the χ<sup>2</sup>-based Q test [<xref ref-type="bibr" rid="pone.0217390.ref039">39</xref>], explored with subgroup analysis [<xref ref-type="bibr" rid="pone.0217390.ref039">39</xref>] and quantified with the I<sup>2</sup> statistic which measures degree of inconsistency among studies [<xref ref-type="bibr" rid="pone.0217390.ref040">40</xref>]. Sources of heterogeneity were detected using the Galbraith plot [<xref ref-type="bibr" rid="pone.0217390.ref041">41</xref>]. Outlier treatment involves omitting the sources of heterogeneity (outliers) followed by reanalysis [<xref ref-type="bibr" rid="pone.0217390.ref042">42</xref>]. Less variability in the study characteristics [<xref ref-type="bibr" rid="pone.0217390.ref043">43</xref>] of the component studies indicate reduced heterogeneity [<xref ref-type="bibr" rid="pone.0217390.ref044">44</xref>]. This warranted use of the fixed-effects model [<xref ref-type="bibr" rid="pone.0217390.ref045">45</xref>], otherwise, we opted for the random-effects model [<xref ref-type="bibr" rid="pone.0217390.ref046">46</xref>]. Sensitivity analysis, which involves omitting one study at a time and recalculating the pooled OR, was used to test for robustness of the summary effects. Differential outcomes between the races and genders warranted the test of interaction [<xref ref-type="bibr" rid="pone.0217390.ref047">47</xref>]. The concept of this test is contextualize the pooled effect of one subgroup (already established by the test of overall effect) by comparing it with its counterpart subgroup (its association independently obtained). In this meta-analysis, the test of interaction involves comparing the pooled ORs and their 95% CIs with their counterparts in the race and gender subgroups (e.g. Western versus Asian, Western versus African, female versus male). A significant Bonferroni corrected P-value of interaction (P<sub>BC</sub> &lt; 0.05) from the z-test means improved power of association. Data were analyzed using Review Manager 5.3 (Cochrane Collaboration, Oxford, England), SIGMASTAT 2.03, SIGMAPLOT 11.0 (Systat Software, San Jose, CA).</p>
</sec>
</sec>
<sec id="sec012" sec-type="results">
<title>Results</title>
<sec id="sec013">
<title>Search results and study features</title>
<p><xref ref-type="fig" rid="pone.0217390.g001">Fig 1</xref>outlines the study selection process in a flowchart following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. A total of 548 citations during the initial search were subjected to a series of omissions. <xref ref-type="supplementary-material" rid="pone.0217390.s003">S2 Table</xref> shows the 38 articles which includes a published thesis [<xref ref-type="bibr" rid="pone.0217390.ref048">48</xref>]. Of the 38, 16 (*) were not included (new) in the 4 previous meta-analyses [<xref ref-type="bibr" rid="pone.0217390.ref010">10</xref>,<xref ref-type="bibr" rid="pone.0217390.ref013">13</xref>,<xref ref-type="bibr" rid="pone.0217390.ref049">49</xref>,<xref ref-type="bibr" rid="pone.0217390.ref050">50</xref>]. Year range of the articles was 2003–2018.</p>
<p>CB score distributions were non-normal (KS: P ≤ 0.002), where median for the 38 studies was 7.0 (IQR 6.0–7.0) indicating high methodological quality of the articles. Confined to the 16 new articles (42.1%), median CB was higher at 8.0 (IQR 7.0–8.0). However, the difference between CB scores in the 38 and 16 studies was marginal (Mann-Whitney U test: P = 0.06). Proportion of articles using blood (65.8%) was higher than those that used saliva or buccal (57.9%) as sources for genotyping. Of note, 9 articles (23.7%) used both sources. Multiple datasets from 5 publications placed the total number of studies to 44 (<xref ref-type="supplementary-material" rid="pone.0217390.s003">S2 Table</xref>). Of the 44 studies, 31 were Western (70.4%), 9 Asian (20.5%) and 4 African (9.0%) subjects.</p>
<p><xref ref-type="supplementary-material" rid="pone.0217390.s004">S3 Table</xref> shows quantitative features of the 44 studies which include sample sizes, number of cases and controls, genotype frequencies, including the minor allele and P-values for HWE. A detailed description of this meta-analysis is summarized in the checklists for PRISMA (<xref ref-type="supplementary-material" rid="pone.0217390.s005">S4 Table</xref>) and for genetic association studies (<xref ref-type="supplementary-material" rid="pone.0217390.s006">S5 Table</xref>).</p>
</sec>
<sec id="sec014">
<title>Meta-analysis outcomes</title>
<p>Here, we emphasize on reporting pooled effects found more in power (MP) rather than in controls (MC). There are two reasons for this emphasis, first, is that power-leaning (MP) effects allow interpretation of results that quantify the magnitude of association. The second reason relates to de-emphasizing the X allele effects which <xref ref-type="table" rid="pone.0217390.t001">Table 1</xref> and <xref ref-type="fig" rid="pone.0217390.g002">Fig 2</xref> show as non-associative (null/MC) in all comparisons. We thus focus on the R allele and RX genotype where significant associative outcomes (P &lt; 0.05) were observed (<xref ref-type="fig" rid="pone.0217390.g002">Fig 2</xref>).</p>
<table-wrap id="pone.0217390.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0217390.t001</object-id>
<label>Table 1</label> <caption><title>Overall analysis of R allele in <italic>ACTN3</italic> R577X polymorphism with power sports.</title></caption>
<alternatives>
<graphic id="pone.0217390.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2"/>
<th align="center" colspan="5">Test of association</th>
<th align="center" colspan="4">Test of heterogeneity</th>
<th align="center" colspan="5">Test of association</th>
<th align="center" colspan="4">Test of heterogeneity</th>
<th align="center" colspan="2">Effect of outlier treatment</th>
</tr>
<tr>
<th align="center">n</th>
<th align="center">OR</th>
<th align="center">95% CI</th>
<th align="left">CID</th>
<th align="left">P<sup>a</sup></th>
<th align="left">Sports Performance</th>
<th align="center">P<sup>b</sup></th>
<th align="center">I<sup>2</sup> (%)</th>
<th align="left">AM</th>
<th align="center">n</th>
<th align="center">OR</th>
<th align="center">95% CI</th>
<th align="left">CID</th>
<th align="left">P<sup>a</sup></th>
<th align="left">Sports Performance</th>
<th align="center">P<sup>b</sup></th>
<th align="center">I<sup>2</sup> (%)</th>
<th align="center">AM</th>
<th align="center" rowspan="2">Signi-ficance</th>
<th align="center" rowspan="2">Hetero geneity</th>
</tr>
<tr>
<th align="center"/>
<th align="center" colspan="9">PRO</th>
<th align="center" colspan="9">PSO</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Overall power</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">R</td>
<td align="center">44</td>
<td align="char" char="."><bold>1.21</bold></td>
<td align="center"><bold>1.07–1.37</bold></td>
<td align="char" char=".">0.30</td>
<td align="left"><bold>0.002</bold></td>
<td align="left">MP</td>
<td align="center">10<sup>−5</sup></td>
<td align="center">61</td>
<td align="left">RE</td>
<td align="center">39</td>
<td align="char" char="."><bold>1.20</bold></td>
<td align="center"><bold>1.12–1.30</bold></td>
<td align="char" char=".">0.18</td>
<td align="left"><bold>10</bold><sup><bold>−5</bold></sup></td>
<td align="left">MP</td>
<td align="center">0.10</td>
<td align="center">23</td>
<td align="center">F</td>
<td align="center">ES</td>
<td align="center">RH</td>
</tr>
<tr>
<td align="left">X</td>
<td align="center">44</td>
<td align="char" char=".">0.71</td>
<td align="center">0.62–0.82</td>
<td align="char" char=".">0.20</td>
<td align="left">10<sup>−5</sup></td>
<td align="left">MC</td>
<td align="center">0.01</td>
<td align="center">35</td>
<td align="left">RE</td>
<td align="center">42</td>
<td align="char" char=".">0.71</td>
<td align="center">0.64–0.79</td>
<td align="char" char=".">0.15</td>
<td align="left">10<sup>−5</sup></td>
<td align="left">MC</td>
<td align="center">0.11</td>
<td align="center">22</td>
<td align="center">F</td>
<td align="center">---</td>
<td align="center">---</td>
</tr>
<tr>
<td align="left">RX</td>
<td align="center">44</td>
<td align="char" char=".">0.90</td>
<td align="center">0.80–1.01</td>
<td align="char" char=".">0.21</td>
<td align="left">0.08</td>
<td align="left">MC</td>
<td align="center">10<sup>−5</sup></td>
<td align="center">62</td>
<td align="left">RE</td>
<td align="center">38</td>
<td align="char" char=".">0.96</td>
<td align="center">0.89–1.04</td>
<td align="char" char=".">0.15</td>
<td align="left">0.30</td>
<td align="left">MC</td>
<td align="center">0.10</td>
<td align="center">24</td>
<td align="center">F</td>
<td align="center">---</td>
<td align="center">---</td>
</tr>
<tr>
<td align="left">Western</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="left"/>
<td align="left"/>
<td align="center"/>
<td align="center"/>
<td align="left"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="left"/>
<td align="left"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">R</td>
<td align="center">31</td>
<td align="char" char="."><bold>1.11</bold></td>
<td align="center"><bold>1.01–1.22</bold></td>
<td align="char" char=".">0.21</td>
<td align="left"><bold>0.02</bold></td>
<td align="left">MP</td>
<td align="center">10<sup>−4</sup></td>
<td align="center">60</td>
<td align="left">RE</td>
<td align="center">28</td>
<td align="char" char="."><bold>1.12</bold></td>
<td align="center"><bold>1.02–1.23</bold></td>
<td align="char" char=".">0.21</td>
<td align="left"><bold>0.01</bold></td>
<td align="left">MP</td>
<td align="center">0.22</td>
<td align="center">16</td>
<td align="center">F</td>
<td align="center">RS</td>
<td align="center">RH</td>
</tr>
<tr>
<td align="left">X</td>
<td align="center">31</td>
<td align="char" char=".">0.78</td>
<td align="center">0.65–0.92</td>
<td align="char" char=".">0.27</td>
<td align="left">0.004</td>
<td align="left">MC</td>
<td align="center">0.02</td>
<td align="center">39</td>
<td align="left">RE</td>
<td align="center">30</td>
<td align="char" char=".">0.81</td>
<td align="center">0.71–0.92</td>
<td align="char" char=".">0.21</td>
<td align="left">0.001</td>
<td align="left">MC</td>
<td align="center">0.13</td>
<td align="center">23</td>
<td align="center">F</td>
<td align="center">---</td>
<td align="center">---</td>
</tr>
<tr>
<td align="left">RX</td>
<td align="center">31</td>
<td align="char" char=".">0.93</td>
<td align="center">0.80–1.07</td>
<td align="char" char=".">0.27</td>
<td align="left">0.31</td>
<td align="left">MC</td>
<td align="center">10<sup>−5</sup></td>
<td align="center">63</td>
<td align="left">RE</td>
<td align="center">28</td>
<td align="char" char=".">1.03</td>
<td align="center">0.95–1.13</td>
<td align="char" char=".">0.18</td>
<td align="left">0.45</td>
<td align="left">Null</td>
<td align="center">0.12</td>
<td align="center">25</td>
<td align="center">F</td>
<td align="center">RNS</td>
<td align="center">RH</td>
</tr>
<tr>
<td align="left">Asian</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="left"/>
<td align="left"/>
<td align="center"/>
<td align="center"/>
<td align="left"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="left"/>
<td align="left"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">R</td>
<td align="center">9</td>
<td align="char" char=".">0.83</td>
<td align="center">0.48–1.43</td>
<td align="char" char=".">0.95</td>
<td align="left">0.49</td>
<td align="left">MC</td>
<td align="center">10<sup>−5</sup></td>
<td align="center">92</td>
<td align="left">RE</td>
<td align="center">7</td>
<td align="char" char=".">1.11</td>
<td align="center">0.65–1.89</td>
<td align="char" char=".">1.29</td>
<td align="left">0.69</td>
<td align="left">MP</td>
<td align="center">10<sup>−5</sup></td>
<td align="center">88</td>
<td align="center">RE</td>
<td align="center">RNS</td>
<td align="center">NC</td>
</tr>
<tr>
<td align="left">X</td>
<td align="center">9</td>
<td align="char" char=".">0.63</td>
<td align="center">0.47–0.83</td>
<td align="char" char=".">0.36</td>
<td align="left">0.001</td>
<td align="left">MC</td>
<td align="center">0.01</td>
<td align="center">60</td>
<td align="left">RE</td>
<td align="center">7</td>
<td align="char" char=".">0.72</td>
<td align="center">0.56–0.92</td>
<td align="char" char=".">0.36</td>
<td align="left">0.008</td>
<td align="left">MC</td>
<td align="center">0.09</td>
<td align="center">45</td>
<td align="center">RE</td>
<td align="center">---</td>
<td align="center">---</td>
</tr>
<tr>
<td align="left">RX</td>
<td align="center">9</td>
<td align="char" char=".">1.43</td>
<td align="center">0.86–2.39</td>
<td align="char" char=".">1.53</td>
<td align="left">0.17</td>
<td align="left">MP</td>
<td align="center">10<sup>−5</sup></td>
<td align="center">95</td>
<td align="left">RE</td>
<td align="center">7</td>
<td align="char" char="."><bold>1.91</bold></td>
<td align="center"><bold>1.25–2.92</bold></td>
<td align="char" char=".">1.67</td>
<td align="left"><bold>0.003</bold></td>
<td align="left">MP</td>
<td align="center">10<sup>−5</sup></td>
<td align="center">91</td>
<td align="center">RE</td>
<td align="center">GS</td>
<td align="center">NC</td>
</tr>
<tr>
<td align="left">African</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="left"/>
<td align="left"/>
<td align="center"/>
<td align="center"/>
<td align="left"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="left"/>
<td align="left"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">R</td>
<td align="center">4</td>
<td align="char" char=".">1.03</td>
<td align="center">0.76–1.40</td>
<td align="char" char=".">0.64</td>
<td align="left">0.83</td>
<td align="left">Null</td>
<td align="center">0.52</td>
<td align="center">0</td>
<td align="left">F</td>
<td align="center">---</td>
<td align="center">---</td>
<td align="center">-------</td>
<td align="center">---</td>
<td align="left">---</td>
<td align="left">---</td>
<td align="center">---</td>
<td align="center">---</td>
<td align="center">---</td>
<td align="center">---</td>
<td align="center">---</td>
</tr>
<tr>
<td align="left">X</td>
<td align="center">4</td>
<td align="char" char=".">0.81</td>
<td align="center">0.34–1.95</td>
<td align="char" char=".">1.61</td>
<td align="left">0.64</td>
<td align="left">MC</td>
<td align="center">0.80</td>
<td align="center">0</td>
<td align="left">F</td>
<td align="center">---</td>
<td align="center">---</td>
<td align="center">-------</td>
<td align="center">---</td>
<td align="left">---</td>
<td align="left">---</td>
<td align="center">---</td>
<td align="center">---</td>
<td align="center">---</td>
<td align="center">---</td>
<td align="center">---</td>
</tr>
<tr>
<td align="left">RX</td>
<td align="center">4</td>
<td align="char" char=".">0.99</td>
<td align="center">0.73–1.36</td>
<td align="char" char=".">0.63</td>
<td align="left">0.96</td>
<td align="left">Null</td>
<td align="center">0.48</td>
<td align="center">0</td>
<td align="left">F</td>
<td align="center">---</td>
<td align="center">---</td>
<td align="center">-------</td>
<td align="center">---</td>
<td align="left">---</td>
<td align="left">---</td>
<td align="center">---</td>
<td align="center">---</td>
<td align="center">---</td>
<td align="center">---</td>
<td align="center">---</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>R: common allele; X: variant allele; RX: heterozygous genotype; n: number of studies; OR: odds ratio; CI: confidence interval; CID: confidence interval difference; P<sup>a</sup>: P-value for association; P<sup>b</sup>: P-value for heterogeneity; I<sup>2</sup>: measure of inconsistency expressed in %; AM: analysis model; PRO: pre-outlier; PSO: post-outlier; F: fixed-effects; RE: random-effects; MP: more in power; MC: more in control; Null (ORs 0.97–1.03); values in bold indicate significant effects on sports performance only (OR &gt; 1.00); the significance and heterogeneity columns were filled when one or both OR values in PRO and/or PSO was MP, otherwise the columns were dashed; ES: elevated significance; RS: retained significance; RNS: retained non-significance; GS: gain in significance; RH: reduced heterogeneity; NC: no change</p></fn>
</table-wrap-foot>
</table-wrap>
<fig id="pone.0217390.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0217390.g002</object-id>
<label>Fig 2</label>
<caption>
<title>3D plot of <italic>ACTN3</italic> polymorphism effects in power sports.</title>
<p>R: wild-type; X: variant-type; RX: heterozygous; MP: more in power; SigMP: significantly more in power.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.g002" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec015">
<title>Overall and race subgroup</title>
<p><xref ref-type="table" rid="pone.0217390.t001">Table 1</xref> shows significant overall associations of the R allele in pre-outlier (PRO) as higher in MP than in MC (OR 1.21, 95% CI 1.07–1.37, P<sup>a</sup> = 0.002), confirmed in the post-outlier (PSO) analysis (OR 1.20, 95% CI 1.12–1.30, P<sup>a</sup> &lt; 10<sup>−5</sup>) and in Westerns (ORs 1.11–1.12, 95% CIs 1.01–1.23, P<sup>a</sup> = 0.01–0.02). Seven (33.3%) of the 21 comparisons in <xref ref-type="table" rid="pone.0217390.t001">Table 1</xref> were MP (OR &gt; 1.00), 5 (71.4%) of which were significant (P<sup>a</sup> &lt; 0.05). Of the 5, pooled effects in Asians were the only subgroup to gain significance (GS) and its heterogeneity unaffected by outlier treatment. Initial homogeneity (I<sup>2</sup> = 0%) of the African non-associative (null/MC) effects (OR 0.81–1.03, 95% CI 0.34–1.95, P<sup>a</sup> = 0.64–0.96) from 4 studies precluded outlier treatment.</p>
</sec>
<sec id="sec016">
<title>Gender analysis</title>
<p><xref ref-type="table" rid="pone.0217390.t002">Table 2</xref> summarizes a total of 11 comparisons, of which 5 (45.5%) show pooled ORs that were higher in MP than in MC. Two of the 5 were significant (P<sup>a</sup> &lt; 0.05), both of which were PSO, underpinning the impact of outlier treatment. Two features mark our core findings in gender analysis regarding associations: (i) the RX genotype in males (OR 1.14, 95% CI 1.02–1.28, P<sup>a</sup> = 0.02) and (ii) the R allele in females (OR 1.58, 95% CI 1.21–2.06, P<sup>a</sup> = 0.0009), but not in males (ORs 1.01–1.06, 95% CI 0.87–1.20, P = 0.31–0.87).</p>
<table-wrap id="pone.0217390.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0217390.t002</object-id>
<label>Table 2</label> <caption><title>Gender analysis in <italic>ACTN3</italic> R577X polymorphism with power sports.</title></caption>
<alternatives>
<graphic id="pone.0217390.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="3"/>
<th align="center" colspan="5">Test of association</th>
<th align="center" colspan="4">Test of heterogeneity</th>
<th align="center" colspan="5">Test of association</th>
<th align="center" colspan="4">Test of heterogeneity</th>
<th align="center" colspan="2">Effect of outlier treatment</th>
</tr>
<tr>
<th align="center">n</th>
<th align="center">OR</th>
<th align="center">95% CI</th>
<th align="left">CID</th>
<th align="left">P<sup>a</sup></th>
<th align="left">Sports Performance</th>
<th align="left">P<sup>b</sup></th>
<th align="center">I<sup>2</sup> (%)</th>
<th align="left">AM</th>
<th align="center">n</th>
<th align="center">OR</th>
<th align="center">95% CI</th>
<th align="left">CID</th>
<th align="left">P<sup>a</sup></th>
<th align="left">Sports Performance</th>
<th align="center">P<sup>b</sup></th>
<th align="center">I<sup>2</sup> (%)</th>
<th align="center">AM</th>
<th align="center" rowspan="2">Signi-ficance</th>
<th align="center" rowspan="2">Hetero-geneity</th>
</tr>
<tr>
<th align="center" colspan="9">PRO</th>
<th align="center" colspan="9">PSO</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Male</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="left"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left">R</td>
<td align="center">20</td>
<td align="char" char=".">1.01</td>
<td align="center">0.87–1.18</td>
<td align="char" char=".">0.31</td>
<td align="char" char=".">0.87</td>
<td align="left">Null</td>
<td align="char" char=".">0.08</td>
<td align="center">33</td>
<td align="left">RE</td>
<td align="center">19</td>
<td align="char" char=".">1.06</td>
<td align="center">0.94–1.20</td>
<td align="char" char=".">0.26</td>
<td align="char" char=".">0.31</td>
<td align="left">MP</td>
<td align="char" char=".">0.47</td>
<td align="center">0</td>
<td align="center">F</td>
<td align="center">RNS</td>
<td align="center">EH</td>
</tr>
<tr>
<td align="left">X</td>
<td align="center">20</td>
<td align="char" char=".">0.75</td>
<td align="center">0.61–0.93</td>
<td align="char" char=".">0.32</td>
<td align="char" char=".">0.008</td>
<td align="left">MC</td>
<td align="char" char=".">0.05</td>
<td align="center">38</td>
<td align="left">RE</td>
<td align="center">19</td>
<td align="char" char=".">0.79</td>
<td align="center">0.67–0.94</td>
<td align="char" char=".">0.27</td>
<td align="char" char=".">0.008</td>
<td align="left">MC</td>
<td align="char" char=".">0.35</td>
<td align="center">8</td>
<td align="center">F</td>
<td align="center">---</td>
<td align="center">---</td>
</tr>
<tr>
<td align="left">RX</td>
<td align="center">20</td>
<td align="char" char=".">1.04</td>
<td align="center">0.87–1.25</td>
<td align="char" char=".">0.38</td>
<td align="char" char=".">0.66</td>
<td align="left">MP</td>
<td align="char" char=".">0.0006</td>
<td align="center">58</td>
<td align="left">RE</td>
<td align="center">19</td>
<td align="char" char="."><bold>1.14</bold></td>
<td align="center"><bold>1.02–1.28</bold></td>
<td align="char" char=".">0.26</td>
<td align="char" char="."><bold>0.02</bold></td>
<td align="left">MP</td>
<td align="char" char=".">0.45</td>
<td align="center">0</td>
<td align="center">F</td>
<td align="center">GS</td>
<td align="center">EH</td>
</tr>
<tr>
<td align="left">Female</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">R</td>
<td align="center">10</td>
<td align="char" char=".">1.39</td>
<td align="center">0.93–2.08</td>
<td align="char" char=".">1.15</td>
<td align="char" char=".">0.11</td>
<td align="left">MP</td>
<td align="char" char=".">0.003</td>
<td align="center">63</td>
<td align="left">RE</td>
<td align="center">8</td>
<td align="char" char="."><bold>1.58</bold></td>
<td align="center"><bold>1.21–2.06</bold></td>
<td align="char" char=".">0.85</td>
<td align="char" char="."><bold>0.0009</bold></td>
<td align="left">MP</td>
<td align="char" char=".">0.11</td>
<td align="center">40</td>
<td align="center">F</td>
<td align="center">GS</td>
<td align="center">RH</td>
</tr>
<tr>
<td align="left">X</td>
<td align="center">10</td>
<td align="char" char=".">0.98</td>
<td align="center">0.66–1.46</td>
<td align="char" char=".">0.80</td>
<td align="char" char=".">0.92</td>
<td align="left">Null</td>
<td align="char" char=".">0.08</td>
<td align="center">42</td>
<td align="left">RE</td>
<td align="center">9</td>
<td align="char" char=".">1.02</td>
<td align="center">0.78–1.31</td>
<td align="char" char=".">0.53</td>
<td align="char" char=".">0.91</td>
<td align="left">Null</td>
<td align="char" char=".">0.10</td>
<td align="center">40</td>
<td align="center">F</td>
<td align="center">RNS</td>
<td align="center">RH</td>
</tr>
<tr>
<td align="left">RX</td>
<td align="center">10</td>
<td align="char" char=".">0.94</td>
<td align="center">0.77–1.15</td>
<td align="char" char=".">0.38</td>
<td align="char" char=".">0.54</td>
<td align="left">MC</td>
<td align="char" char=".">0.21</td>
<td align="center">25</td>
<td align="left">F</td>
<td align="center">---</td>
<td align="center">---</td>
<td align="center">-------</td>
<td align="center">-----</td>
<td align="center">---</td>
<td align="left">---</td>
<td align="center">---</td>
<td align="center">---</td>
<td align="center">---</td>
<td align="center">---</td>
<td align="center">---</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>R: common allele; X: variant allele; RX: heterozygous genotype; n: number of studies; OR: odds ratio; CI: confidence interval; CID: confidence interval difference; P<sup>a</sup>: P-value for association; P<sup>b</sup>: P-value for heterogeneity; I<sup>2</sup>: measure of inconsistency expressed in %; AM: analysis model; PRO: pre-outlier; PSO: post-outlier; F: fixed-effects; RE: random-effects; MP: more in power; MC: more in control; Null (ORs 0.97–1.03); values and indicator (SP) in bold indicate significant associations indicating effects on SP only (OR &gt; 1.00); the significance and heterogeneity columns were filled when one or both OR values in PRO and/or PSO was MP, otherwise the columns were dashed; GS: gain in significance; RNS: retained non-significance; EH: eliminated heterogeneity; RH: reduced heterogeneity</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec017">
<title>Mechanism of outlier treatment</title>
<p>Operation of outlier treatment is outlined in Figs <xref ref-type="fig" rid="pone.0217390.g003">3</xref>–<xref ref-type="fig" rid="pone.0217390.g005">5</xref> for the R allele comparison among females with ORs that favor MP over MC. In <xref ref-type="fig" rid="pone.0217390.g003">Fig 3</xref>, the pooled effect (OR 1.39, 95% CI 0.93–2.08) was not significant (P<sup>a</sup> = 0.11) and heterogeneous (P<sup>b</sup> = 0.003, I<sup>2</sup> = 63%). The sources of this heterogeneity were identified [<xref ref-type="bibr" rid="pone.0217390.ref030">30</xref>,<xref ref-type="bibr" rid="pone.0217390.ref051">51</xref>] with the Galbraith plot (<xref ref-type="fig" rid="pone.0217390.g004">Fig 4</xref>). <xref ref-type="fig" rid="pone.0217390.g005">Fig 5</xref> shows the PSO value of acquired significance (P<sup>a</sup> = 0.0009) and reduced heterogeneity (P<sup>b</sup> = 0.11, I<sup>2</sup> = 40%) with pooled female effect of the R allele higher in MP compared to MC (OR 1.58, 95% CI 1.21–2.06, P<sup>a</sup> = 0.0009).</p>
<fig id="pone.0217390.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0217390.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Forest plot of the R allele female effects in the pre-outlier analysis.</title>
<p>R: wild-type; CI: confidence interval; P: P-value; χ<sup>2</sup>: chi-square; CID: confidence interval difference.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.g003" xlink:type="simple"/>
</fig>
<fig id="pone.0217390.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0217390.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Galbraith plot of the female subgroup in the R allele showing the outlying studies found below the -2 confidence limit.</title>
<p>R: wild-type.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.g004" xlink:type="simple"/>
</fig>
<fig id="pone.0217390.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0217390.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Forest plot of the R allele female effects in the post-outlier analysis.</title>
<p>R: wild-type; CI: confidence interval; P: P-value; χ<sup>2</sup>: chi-square; CID: confidence interval difference.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.g005" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec018">
<title>Effects of outlier treatment</title>
<p><xref ref-type="table" rid="pone.0217390.t003">Table 3</xref> presents the trends from PRO to PSO outcomes using four parameters (high significance, heterogeneity, homogeneity and precision). In the subgroups, high significance declined (20% to 9%) as did heterogeneity (73% to 27%). In the overall analysis, however, heterogeneity disappeared (100% to 0%). Outlier treatment did not appear to impact on homogeneity in all comparisons. The precision parameter (indicated by CID) shows that the PRO and PSO values had normal distributions in the overall (KS: P = 0.09–0.16) but not the subgroups (KS: P = 0.002–0.01). For both comparisons, the PSO values were less than PRO with the overall mean ± SD (0.16 ± 0.02 &lt; 0.24 ± 0.06) and subgroup median (IQR) of 0.27 (0.22–0.77) &lt; 0.36 (0.28–0.91). However, the CID differences were not significant in the overall analysis (t = 2.30, P = 0.08) and the subgroups (U = 47.50, P = 0.41). Despite their non-significance, these differences suggest increase in precision.</p>
<table-wrap id="pone.0217390.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0217390.t003</object-id>
<label>Table 3</label> <caption><title>Effects of outlier treatment in power sports outcomes.</title></caption>
<alternatives>
<graphic id="pone.0217390.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="left"/>
<th align="center" colspan="2">Overall</th>
<th align="center" colspan="2">Subgroups</th>
</tr>
<tr>
<th align="left">Parameter</th>
<th align="left">Indicator</th>
<th align="left">PRO n/Total (%)</th>
<th align="left">PSO n/Total (%)</th>
<th align="left">PRO n/Total (%)</th>
<th align="left">PSO n/Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">High significance</td>
<td align="left">P &lt; 10<sup>−5</sup></td>
<td align="left">0/3 (0)</td>
<td align="left">0/3 (0)</td>
<td align="left">3/15 (20)</td>
<td align="left">1/11 (9)</td>
</tr>
<tr>
<td align="left">Heterogeneity</td>
<td align="left">Random-effects</td>
<td align="left">3/3 (100)</td>
<td align="left">0/3 (0)</td>
<td align="left">11/15 (73)</td>
<td align="left">3/11 (27)</td>
</tr>
<tr>
<td align="left">Homogeneity</td>
<td align="left">I<sup>2</sup> = 0%</td>
<td align="left">0/3 (0)</td>
<td align="left">0/3 (0)</td>
<td align="left">3/11 (20)</td>
<td align="left">2/11 (18)</td>
</tr>
<tr>
<td align="left">Precision <xref ref-type="table-fn" rid="t003fn003">**</xref></td>
<td align="left">CID<xref ref-type="table-fn" rid="t003fn002">*</xref></td>
<td align="left">0.24 ± 0.06</td>
<td align="left">0.16 ± 0.02</td>
<td align="left">0.36 (0.28–0.91)</td>
<td align="left">0.27 (0.22–0.77)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p>PRO: pre-outlier; PSO: post-outlier; CID: confidence interval difference;</p></fn>
<fn id="t003fn002"><p>* mean ± standard deviation for overall; median (interquartile range) for subgroups;</p></fn>
<fn id="t003fn003"><p>** CID comparison between PRO and PSO in overall (t-test: t = 2.30, P = 0.08) and subgroups (Mann-Whitney U test: U = 47.50, P = 0.41)</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec019">
<title>Tests of interaction</title>
<p>Interaction tests were performed on the significant R allele and RX genotype subgroup outcomes. <xref ref-type="table" rid="pone.0217390.t004">Table 4</xref> shows that of the 5 comparisons subjected to these tests, only the significant female effect (OR 1.58, P = 0.0009) compared with that of the non-significant male effect (OR 1.06, P = 0.31) resulted in significant interaction (P<sub>interaction BC</sub> = 0.03) suggesting improved association. This comparative outcome strengthens the statistical evidence favoring the MP female effect.</p>
<table-wrap id="pone.0217390.t004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0217390.t004</object-id>
<label>Table 4</label> <caption><title>Tests of interaction.</title></caption>
<alternatives>
<graphic id="pone.0217390.t004g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.t004" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Outlier status</th>
<th align="left">Genetic component</th>
<th align="center">a</th>
<th align="center"/>
<th align="center">b</th>
<th align="center">OR<sup>a</sup></th>
<th align="center">v</th>
<th align="center">OR<sup>b</sup></th>
<th align="left">Uncorrected P<sub>interaction</sub></th>
<th align="left">Corrected P<sub>interaction BC</sub></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">PRO</td>
<td align="left">R</td>
<td align="left">Western</td>
<td align="center">v</td>
<td align="right">Asian</td>
<td align="char" char="."><bold>1.11</bold></td>
<td align="center">v</td>
<td align="char" char=".">0.83</td>
<td align="char" char=".">0.30</td>
<td align="left">&gt;1</td>
</tr>
<tr>
<td align="left">PSO</td>
<td align="left">R</td>
<td align="left">Western</td>
<td align="center">v</td>
<td align="right">Asian</td>
<td align="char" char="."><bold>1.12</bold></td>
<td align="center">v</td>
<td align="char" char=".">1.11</td>
<td align="char" char=".">0.97</td>
<td align="left">&gt;1</td>
</tr>
<tr>
<td align="left">PRO</td>
<td align="left">R</td>
<td align="left">Western</td>
<td align="center">v</td>
<td align="right">African</td>
<td align="char" char="."><bold>1.11</bold></td>
<td align="center">v</td>
<td align="char" char=".">1.03</td>
<td align="char" char=".">0.64</td>
<td align="left">&gt;1</td>
</tr>
<tr>
<td align="left">PSO</td>
<td align="left">RX</td>
<td align="left">Asian</td>
<td align="center">v</td>
<td align="right">Western</td>
<td align="char" char="."><bold>1.91</bold></td>
<td align="center">v</td>
<td align="char" char=".">1.03</td>
<td align="char" char="."><bold>0.012</bold></td>
<td align="left">0.06</td>
</tr>
<tr>
<td align="left">PSO</td>
<td align="left">R</td>
<td align="left">Female</td>
<td align="center">v</td>
<td align="right">Male</td>
<td align="char" char="."><bold>1.58</bold></td>
<td align="center">v</td>
<td align="char" char=".">1.06</td>
<td align="char" char="."><bold>0.007</bold></td>
<td align="left"><bold>0.03</bold></td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t004fn001"><p>PRO: pre-outlier; PSO: post-outlier; R: common allele; RX: heterozygous genotype; v: versus; OR: odds ratio; a: subgroup with significant ORs; b: subgroup with non-significant ORs; P-values were Bonferroni-corrected (<sub>BC</sub>). Values in bold indicate significance (P &lt; 0.05) of associations (under OR<sup>a</sup>) and P-values (corrected and uncorrected)</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec020">
<title>Sensitivity analysis</title>
<p>In this section, we focused only the significant MP pooled ORs. <xref ref-type="table" rid="pone.0217390.t005">Table 5</xref> shows robust outcomes in the following: (i) more in PSO than in PRO; (ii) in the overall analyses regardless of outlier status; (iii) in the subgroups, only race in PSO and in gender, only female and (iv) as to genetic component, in the R allele more than in the RX genotype.</p>
<table-wrap id="pone.0217390.t005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0217390.t005</object-id>
<label>Table 5</label> <caption><title>Sensitivity analysis.</title></caption>
<alternatives>
<graphic id="pone.0217390.t005g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.t005" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Comparison</th>
<th align="left">Genetic component</th>
<th align="left">Outlier status</th>
<th align="left">Sensitivity outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Overall</td>
<td align="left">R</td>
<td align="left">PRO</td>
<td align="left">Robust</td>
</tr>
<tr>
<td align="left">Overall</td>
<td align="left">R</td>
<td align="left">PSO</td>
<td align="left">Robust</td>
</tr>
<tr>
<td align="left">Western</td>
<td align="left">R</td>
<td align="left">PRO</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0217390.ref004">4</xref>,<xref ref-type="bibr" rid="pone.0217390.ref052">52</xref>]</td>
</tr>
<tr>
<td align="left">Western</td>
<td align="left">R</td>
<td align="left">PSO</td>
<td align="left">Robust</td>
</tr>
<tr>
<td align="left">Asian</td>
<td align="left">RX</td>
<td align="left">PSO</td>
<td align="left">Robust</td>
</tr>
<tr>
<td align="left">Male</td>
<td align="left">RX</td>
<td align="left">PSO</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0217390.ref030">30</xref>,<xref ref-type="bibr" rid="pone.0217390.ref053">53</xref>–<xref ref-type="bibr" rid="pone.0217390.ref057">57</xref>]</td>
</tr>
<tr>
<td align="left">Female</td>
<td align="left">R</td>
<td align="left">PSO</td>
<td align="left">Robust</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t005fn001"><p>R: common allele; RX: heterozygous genotype; PRO: pre-outlier; PSO: post-outlier; presence of reference number indicates intervening studies</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec021">
<title>Publication bias</title>
<p>Study-specific ORs under each of R and RX genetic components showed the non-normal distribution of the operating data (KS test: P = 0.002–0.02). Given this data distribution, we used the Begg-Mazumdar correlation [<xref ref-type="bibr" rid="pone.0217390.ref036">36</xref>] to assess publication bias. We applied this test on comparisons with &gt; 10 studies [<xref ref-type="bibr" rid="pone.0217390.ref058">58</xref>] and those with significant outcomes only. <xref ref-type="table" rid="pone.0217390.t006">Table 6</xref> shows no evidence of publication bias in all comparisons (P &gt; 0.05).</p>
<table-wrap id="pone.0217390.t006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0217390.t006</object-id>
<label>Table 6</label> <caption><title>Test for publication bias.</title></caption>
<alternatives>
<graphic id="pone.0217390.t006g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.t006" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="left"/>
<th align="left"/>
<th align="left"/>
<th align="center" colspan="2">Begg Mazumdar correlation test</th>
</tr>
<tr>
<th align="right">Group/subgroup</th>
<th align="left">Genetic component</th>
<th align="center">Outlier status</th>
<th align="center">n</th>
<th align="center">Kendall τ</th>
<th align="center">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="right">Overall</td>
<td align="left">R</td>
<td align="center">PRO</td>
<td align="center">44</td>
<td align="char" char=".">-0.08</td>
<td align="char" char=".">0.45</td>
</tr>
<tr>
<td align="right">Overall</td>
<td align="left">R</td>
<td align="center">PSO</td>
<td align="center">38</td>
<td align="char" char=".">-0.10</td>
<td align="char" char=".">0.39</td>
</tr>
<tr>
<td align="right">Western</td>
<td align="left">R</td>
<td align="center">PRO</td>
<td align="center">31</td>
<td align="char" char=".">-0.03</td>
<td align="char" char=".">0.84</td>
</tr>
<tr>
<td align="right">Western</td>
<td align="left">R</td>
<td align="center">PSO</td>
<td align="center">28</td>
<td align="char" char=".">-0.09</td>
<td align="char" char=".">0.52</td>
</tr>
<tr>
<td align="right">Male</td>
<td align="left">RX</td>
<td align="center">PSO</td>
<td align="center">20</td>
<td align="char" char=".">-0.05</td>
<td align="char" char=".">0.75</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t006fn001"><p>R: common allele; RX: heterozygous genotype; PRO: pre-outlier; PSO: post-outlier; n: number of studies</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="sec022" sec-type="conclusions">
<title>Discussion</title>
<p>This meta-analysis has two principal findings: (i) overall associations of the R allele and RX genotype with PS performance were validated with outlier and subgroup treatments and (ii) the R allele was associated with Westerns and females whereas the RX genotype was associated with Asians and males. Gender-wise, the R allele effects differed between males and females. The significant Asian and male/female outcomes were the results of outlier treatment. This treatment impacted on heterogeneity (reduced or eliminated) of the gender outcomes, but not the Asian outcomes. Thus, retention of heterogeneity in the PSO Asian pooled effects warrants caution in its interpretation.</p>
<p>A total sample size of 20,753 individuals for this meta-analysis seems large until this number is contextualized in terms of the controls (n = 15,903) which is &gt; 3X those of the athletes (n = 4,850). In the Western subgroup of Wang et al [<xref ref-type="bibr" rid="pone.0217390.ref022">22</xref>], there were 13 controls for every 1 athlete participant (n = 1,694/130). The gap between large numbers of controls and few elite athlete participants reduces statistical power. This then may be one reason why genetic association studies of elite sports performance have low statistical power [<xref ref-type="bibr" rid="pone.0217390.ref008">8</xref>]. In view of this limitation, the meta-analysis approach, with its aggregate sample sizes may be suitable for examining association of <italic>ACTN3</italic> R577X with PS performance.</p>
<sec id="sec023">
<title>Significance of the findings</title>
<p>The <italic>ACTN3</italic> R577X polymorphism has a repeated influence on elite athletic performance [<xref ref-type="bibr" rid="pone.0217390.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0217390.ref057">57</xref>]. This is why improved levels of evidence need to be presented from several front-line studies. The association between the <italic>ACTN3</italic> R577X polymorphism on elite PS performance has been established across studies that have employed differing methodologies. Our findings of RR and RX associations with PS appear to agree with both human [<xref ref-type="bibr" rid="pone.0217390.ref059">59</xref>] and animal studies [<xref ref-type="bibr" rid="pone.0217390.ref060">60</xref>]. Compared with X allele carriers, studies have shown that RR genotype and R allele carriers may have more muscle size and strength [<xref ref-type="bibr" rid="pone.0217390.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0217390.ref061">61</xref>,<xref ref-type="bibr" rid="pone.0217390.ref062">62</xref>], faster sprint times [<xref ref-type="bibr" rid="pone.0217390.ref063">63</xref>] and a higher proportion of fast-twitch muscle fibers [<xref ref-type="bibr" rid="pone.0217390.ref059">59</xref>,<xref ref-type="bibr" rid="pone.0217390.ref064">64</xref>]. Likewise, PS athletes have been reported to have a higher frequency of the RR + RX genotype (presence of α-actinin-3 protein) in their fast-twitch skeletal muscle compared to controls [<xref ref-type="bibr" rid="pone.0217390.ref004">4</xref>]. However, not all studies agree with these findings [<xref ref-type="bibr" rid="pone.0217390.ref025">25</xref>,<xref ref-type="bibr" rid="pone.0217390.ref065">65</xref>–<xref ref-type="bibr" rid="pone.0217390.ref068">68</xref>]. Nevertheless, the importance of <italic>ACTN3</italic> in muscle structure and phenotype [<xref ref-type="bibr" rid="pone.0217390.ref063">63</xref>,<xref ref-type="bibr" rid="pone.0217390.ref069">69</xref>] directly affects elite PS performance. In our study, marginalizing the role of the X allele in the PS phenotype was based on their control-leaning (MC) and/or null effects as well as non-significance which warranted a neutral position as to its role in PS. We maintain this neutrality, despite the suggestion that the XX genotype is detrimental for elite sprint and power performance [<xref ref-type="bibr" rid="pone.0217390.ref070">70</xref>].</p>
</sec>
<sec id="sec024">
<title>Subgroup significance</title>
<p>Differential findings delineated the associations between the races. Outcomes in Africans were marginalized in view of their non-associative (null/MC) effects across comparisons. Conversely, there were significant and associative effects in Westerners (R allele in PRO and PSO) and Asians (RX genotype in PSO) and these formed the core of our subgroup findings. The RR and RX associations found in our study seem to agree with studies of Japanese and Caucasian (Western) PS athletes with higher frequencies of RR and RX than controls [<xref ref-type="bibr" rid="pone.0217390.ref004">4</xref>,<xref ref-type="bibr" rid="pone.0217390.ref023">23</xref>,<xref ref-type="bibr" rid="pone.0217390.ref053">53</xref>]. On the protein level, presence of <italic>α-actinin-3</italic> in fast-twitch skeletal muscle fibers (RR and RX genotypes at the gene level), was associated with PS performance in elite Japanese athletes [<xref ref-type="bibr" rid="pone.0217390.ref027">27</xref>]. Not only do the RR and RX genotypes have associations with the PS phenotype across race lines, they also cross athletic status as well, with incremental frequencies from regional to national to international levels for PS athletes [<xref ref-type="bibr" rid="pone.0217390.ref004">4</xref>,<xref ref-type="bibr" rid="pone.0217390.ref055">55</xref>,<xref ref-type="bibr" rid="pone.0217390.ref071">71</xref>].</p>
<p>Gender analysis of the R allele shows significance in females but not in males indicating the lack of support for PS in men, but with validated outcome in women. This R allele gender difference seems at odds with the men’s outcome that did not show enrichment for the RR genotype but did for the RX. Our significant male RX finding appears to contrast with the primary study of Ruiz et al. [<xref ref-type="bibr" rid="pone.0217390.ref056">56</xref>] who reported absence of heterozygous advantage for Spanish elite male athletes. Reasons for this disparity may be methodological which include limited statistical power, hidden confounding factors, and/or misdefined phenotypes [<xref ref-type="bibr" rid="pone.0217390.ref032">32</xref>]. The R allele/RR genotype appears to influence relative peak power in Japanese male athletes [<xref ref-type="bibr" rid="pone.0217390.ref027">27</xref>] and impact upon elite status among Taiwanese female sprint swimmers [<xref ref-type="bibr" rid="pone.0217390.ref070">70</xref>]. Regarding response to exercise training, women with the RR genotype (compared to XX genotype carriers) had lower muscle leg power initially but had greater increases after strength training [<xref ref-type="bibr" rid="pone.0217390.ref012">12</xref>].</p>
</sec>
<sec id="sec025">
<title><italic>ACTN3</italic> and previous meta-analyses</title>
<p>A recent 2018 publication (Garton et al) on the effect of the <italic>ACTN3</italic> gene on skeletal muscle performance included a meta-analysis that evaluated gene dosage effects using the Bayesian random-effects model [<xref ref-type="bibr" rid="pone.0217390.ref050">50</xref>]. Because this statistical approach diverges from ours, we compare from the viewpoints of study number differences and genetic outcomes. From a total of 12 studies, they found a homozygote effect (R allele) of 1.4-fold, while our overall R allele outcome was 1.2-fold from 44 studies (PRO). They also reported substantial heterogeneity in the heterozygote RX effect (OR 0.98). Our overall PRO RX effect (OR = 0.90) was also heterogeneous (I<sup>2</sup> = 62%). However, our outlier results yielded fixed-effects outcomes (PSO) for the R allele and RX genotype which addressed and resolved the heterogeneity issue. Garton et al [<xref ref-type="bibr" rid="pone.0217390.ref050">50</xref>] found that race and gender were unlikely variables that explain homozygote (R) and dominant (RX) effects. In contrast, we delineated race and gender effects with subgroup analysis. They concluded that no single genetic model explains the association between <italic>ACTN3</italic> and PS [<xref ref-type="bibr" rid="pone.0217390.ref050">50</xref>]. In contrast, our use of allele-genotype modeling yielded clear <italic>ACTN3</italic> R allele and RX genotype associations with PS.</p>
<p>Because similar methodologies were used in the 3 previous meta-analyses [<xref ref-type="bibr" rid="pone.0217390.ref010">10</xref>,<xref ref-type="bibr" rid="pone.0217390.ref013">13</xref>,<xref ref-type="bibr" rid="pone.0217390.ref049">49</xref>], we are able to systematically compare each of their findings with ours (<xref ref-type="supplementary-material" rid="pone.0217390.s007">S6 Table</xref>). Weyerstraß et al [<xref ref-type="bibr" rid="pone.0217390.ref049">49</xref>] and Alfred et al [<xref ref-type="bibr" rid="pone.0217390.ref013">13</xref>] presented results exclusively from examining PS performance, while Ma et al [<xref ref-type="bibr" rid="pone.0217390.ref010">10</xref>] pooled data from power, endurance and mixed sports. <xref ref-type="supplementary-material" rid="pone.0217390.s007">S6 Table</xref> compares the overall outcomes based on the R allele and shows where meta-analysis treatments were applied and where they were not. Our use of outlier treatment facilitated a shift from PRO to PSO rendering changes in significance (elevated or gained) and heterogeneity (reduced or eliminated). Despite these dynamic shifts being unaddressed in the previous meta-analyses, our overall pooled OR is similar to those of Ma et al [<xref ref-type="bibr" rid="pone.0217390.ref010">10</xref>] and Alfred et al [<xref ref-type="bibr" rid="pone.0217390.ref013">13</xref>] but not Weyerstraß et al [<xref ref-type="bibr" rid="pone.0217390.ref049">49</xref>]. In the race subgroups, the <italic>ACTN3</italic> R577X genotype was associated with PS performance among Europeans (Westerns) in Alfred et al [<xref ref-type="bibr" rid="pone.0217390.ref013">13</xref>] but not Ma et al [<xref ref-type="bibr" rid="pone.0217390.ref010">10</xref>] and Weyerstraß et al [<xref ref-type="bibr" rid="pone.0217390.ref049">49</xref>]. All three meta-analyses showed no such associations in Asians and/or African athletes.</p>
</sec>
<sec id="sec026">
<title>Comparisons with other studies</title>
<p>The hypothesis that the <italic>ACTN3</italic> R allele may confer some advantage in PS is supported by cross-sectional studies in elite athletes and non-athletes as well as mouse models of <italic>ACTN3</italic> deficiency [<xref ref-type="bibr" rid="pone.0217390.ref002">2</xref>,<xref ref-type="bibr" rid="pone.0217390.ref060">60</xref>,<xref ref-type="bibr" rid="pone.0217390.ref072">72</xref>,<xref ref-type="bibr" rid="pone.0217390.ref073">73</xref>]. In <italic>ACTN3</italic> knockout mice, the loss-of-function variant for the XX genotype resulted in eliminated expression of the <italic>α-actinin-3</italic> protein [<xref ref-type="bibr" rid="pone.0217390.ref060">60</xref>,<xref ref-type="bibr" rid="pone.0217390.ref069">69</xref>,<xref ref-type="bibr" rid="pone.0217390.ref074">74</xref>]. Such deficiency has been shown to reduce fast-twitch muscle fiber diameter, muscle mass and strength. Moreover, studies of athletes with the RR or RX genotype are associated with high muscle strength and power compared to those with the XX genotype [<xref ref-type="bibr" rid="pone.0217390.ref007">7</xref>]. This appears concordant with our R allele and RX genotype findings. Several case-control association studies have reported that the RR genotype is over-represented or the XX genotype is under-represented in strength and power athletes in comparison with controls [<xref ref-type="bibr" rid="pone.0217390.ref004">4</xref>,<xref ref-type="bibr" rid="pone.0217390.ref072">72</xref>].</p>
</sec>
<sec id="sec027">
<title><italic>ACTN3</italic> and GWAS</title>
<p>The polygenic nature of gene involvement in sports performance generated studies to investigate this aspect of sports genetics. Other than haplotype and interaction studies, examining several genes simultaneously using GWAS appears to be the current fashion in genomics. In 2019, Jacques et al [<xref ref-type="bibr" rid="pone.0217390.ref075">75</xref>] summarized current advances in the genetics of sports performance and covered GWAS and <italic>ACTN3</italic> in separate sections exclusive of each other. Five years earlier (2014), a GWAS and meta-analysis study was performed on African-American and Asian (Japanese) sprint (power) athletes and identified two loci of putative interest [<xref ref-type="bibr" rid="pone.0217390.ref048">48</xref>] but did not include the <italic>ACTN3</italic> R577X polymorphism. The two PS GWAS in the literature examined grip strength and sprint but they did not include <italic>ACTN3</italic> which suggests the nascent status of the GWAS approach. A literature search yielded no other GWAS undertakings related to <italic>ACTN3</italic>, attesting to the paucity of studies in this area. Nevertheless, whole genome analysis of elite athletes has been predicted to reshape the current understanding of the genetic basis of athletic performance [<xref ref-type="bibr" rid="pone.0217390.ref076">76</xref>,<xref ref-type="bibr" rid="pone.0217390.ref077">77</xref>].</p>
</sec>
<sec id="sec028">
<title><italic>ACTN3</italic> R577X effects on longevity</title>
<p>Beyond the prestige of elite sports performance in power rests the long term issue of skeletal muscle integrity, which is an overriding concern in a human’s lifetime, more so in the elderly. Knowledge of the genetic influence of <italic>ACTN3</italic> R577X on elderly populations could potentially affect health care and treatment for this segment of society. The <italic>ACTN3</italic> R577X genotype exhibits a potential modifying effect on muscle deterioration (sarcopenia), which is associated with aging [<xref ref-type="bibr" rid="pone.0217390.ref078">78</xref>]. Given the importance of resistance training in preventing and treating sarcopenia [<xref ref-type="bibr" rid="pone.0217390.ref079">79</xref>], the <italic>ACTN3</italic> R577X genotype could modify resistance training adaptations [<xref ref-type="bibr" rid="pone.0217390.ref007">7</xref>]. In particular, the R allele is associated with greater adaptive response to training [<xref ref-type="bibr" rid="pone.0217390.ref011">11</xref>] and protects against the development of sarcopenia [<xref ref-type="bibr" rid="pone.0217390.ref080">80</xref>]. The consensus is that the RR genotype is associated with enhanced strength and power improvements. The protective action of the RR genotype against sarcopenia is then expected among the elderly because of its potential association with better health. However, genetic data on centenarians (≥ 100 years of age) show otherwise. In two studies of Japanese and Spanish centenarians, the XX genotype frequency was reported at 23.7% and 24%, respectively, significant in the latter (P = 0.01) but not the former (P = 0.75) when compared with controls [<xref ref-type="bibr" rid="pone.0217390.ref081">81</xref>,<xref ref-type="bibr" rid="pone.0217390.ref082">82</xref>]. Moreover, frequency of the XX genotype in supercentenarians (&gt; 110 years old) was even higher at 33% [<xref ref-type="bibr" rid="pone.0217390.ref081">81</xref>]. In addition, North et al [<xref ref-type="bibr" rid="pone.0217390.ref083">83</xref>] found that the XX genotype was associated with enhanced cardiovascular fitness. These data suggest a potential survival advantage of the XX genotype impacting old people [<xref ref-type="bibr" rid="pone.0217390.ref081">81</xref>]. The R allele, on the other hand, was shown to be associated with reduced frailty risk [<xref ref-type="bibr" rid="pone.0217390.ref080">80</xref>]. Unlike the X allele, however, the R allele is uncommon in the very old population. Thus, the inverse relationship of the R allele with longevity renders RX heterozygotes the most benefit given the advantages associated with each allele [<xref ref-type="bibr" rid="pone.0217390.ref080">80</xref>]. The study of Garatachea et al (2011) further complicates the <italic>ACTN3</italic>-longevity issue, where they found no associations of the <italic>ACTN3</italic> genotypes with muscle phenotypes in octogenarians [<xref ref-type="bibr" rid="pone.0217390.ref084">84</xref>]. In view of all these findings, associations of the two alleles (R or X) with human longevity remain complicated and their results controversial [<xref ref-type="bibr" rid="pone.0217390.ref082">82</xref>]. Future studies may require greater sample sizes to resolve this impasse.</p>
</sec>
<sec id="sec029">
<title>Strengths and limitations</title>
<p>The interpretation of our findings is best contextualized in view of its limitations and strengths. The limitations include: (i) statistical heterogeneity; (ii) possible admixtures of the Western subgroup; (iii) dominating presence of Western studies under-represented the Asian and African populations; (iv) only 8 included articles (21.1%) matched their controls with athlete participants; (v) that some included studies contain elements of endurance and mixed sports in the performance (e.g. team sports) might dilute the impact of our PS findings. On the other hand, the strengths comprise of the following: (i) confining our analysis to HWE-compliant studies effectively screened for genotyping errors, thus minimizing methodological weaknesses to the summary outputs [<xref ref-type="bibr" rid="pone.0217390.ref085">85</xref>]; (ii) overall methodological quality (determined by CB) of the included studies was high; (iii) 87% (33/38 articles) of the controls were defined as healthy indicating lack of heterogeneity; (iv) 71% (5/7 comparisons) of the sensitivity treatment outcomes were robust and (v) a 43% increase (from 19 studies in Weyerstraß et al [<xref ref-type="bibr" rid="pone.0217390.ref049">49</xref>] to 44 in this meta-analysis) in the number of included studies raised the total sample size. This enhanced the statistical power to assess associations in this study and may have minimized false-positive outcomes [<xref ref-type="bibr" rid="pone.0217390.ref042">42</xref>]. Our use of outlier treatment in this study also has strengths and limitations. We have shown that this treatment is an effective meta-analysis tool in addressing heterogeneity. However, the caveat of outlier treatment is that it reduces statistical power but is more impactful when the number of studies is few (e.g. &lt; 10). We recognize that elite athlete status is a complex condition. Whilst few articles (6 and 4, respectively) mentioned gene-gene interaction and haplotypes, considerably more (20/38 articles) addressed the importance of gene-environment interplay (<xref ref-type="supplementary-material" rid="pone.0217390.s003">S2 Table</xref>).</p>
</sec>
<sec id="sec030">
<title>Practical applications</title>
<p>Strengthened evidence from this meta-analysis could establish the <italic>ACTN3</italic> gene to form part of the genetic repertoire for identifying elite athletes with PS potential. The future of genetic testing for talent identification of elite sprint and power athletes has been posited to include the <italic>ACTN3</italic> R577X genotype [<xref ref-type="bibr" rid="pone.0217390.ref070">70</xref>]. In fact, a genetic-based algorithm (which includes <italic>ACTN3</italic>) has been proposed to determine training response by predicting potential for athletic performance [<xref ref-type="bibr" rid="pone.0217390.ref080">80</xref>]. However, reaction to this proposal has been viewed as premature, warranting caution in terms of its interpretation and implementation [<xref ref-type="bibr" rid="pone.0217390.ref084">84</xref>]. At present, the nascent status of the influence of genetic polymorphisms in sports precludes the recommendation of genetic testing to optimize athletic performance [<xref ref-type="bibr" rid="pone.0217390.ref048">48</xref>].</p>
</sec>
<sec id="sec031">
<title>Conclusions</title>
<p>Focusing on a single but notable polymorphism (<italic>ACTN3</italic> R577X) affecting PS performance [<xref ref-type="bibr" rid="pone.0217390.ref001">1</xref>] has allowed application of a number of meta-analytical procedures which unraveled detailed associations. These procedures managed to uncover findings that were not obvious in the component studies which we hope to have augmented existing evidence for <italic>ACTN3</italic> R577X associations with PS status. Varying depths of supporting evidence are important in replicating significant results [<xref ref-type="bibr" rid="pone.0217390.ref008">8</xref>]. The MP overall effect of the R allele in <italic>ACTN3</italic> R577X may be modest, but its replicative behavior observed in the subgroups likely establishes its role in enhancing PS performance.</p>
</sec>
</sec>
<sec id="sec032">
<title>Supporting information</title>
<supplementary-material id="pone.0217390.s001" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.s001" xlink:type="simple">
<label>S1 List</label>
<caption>
<title>Excluded studies.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0217390.s002" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.s002" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Excluded studies based on HWE.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0217390.s003" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.s003" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>Included studies.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0217390.s004" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.s004" xlink:type="simple">
<label>S3 Table</label>
<caption>
<title>Quantitative data of <italic>ACTN3</italic> R577X polymorphism studies.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0217390.s005" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.s005" xlink:type="simple">
<label>S4 Table</label>
<caption>
<title>PRISMA checklist.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0217390.s006" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.s006" xlink:type="simple">
<label>S5 Table</label>
<caption>
<title>Meta-analysis of genetic association checklist.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0217390.s007" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0217390.s007" xlink:type="simple">
<label>S6 Table</label>
<caption>
<title>Comparisons with other meta-analyses.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item><term>[R]</term>
<def><p>Reference number</p></def>
</def-item>
<def-item><term>A</term>
<def><p>Alfred et al.</p></def>
</def-item>
<def-item><term>a</term>
<def><p>Subgroup with significant ORs</p></def>
</def-item>
<def-item><term><italic>ACTN3</italic></term>
<def><p><italic>alpha-actinin-3</italic></p></def>
</def-item>
<def-item><term>AfAm</term>
<def><p>African American</p></def>
</def-item>
<def-item><term>AM</term>
<def><p>Analysis model</p></def>
</def-item>
<def-item><term>b</term>
<def><p>Subgroup with non-significant ORs</p></def>
</def-item>
<def-item><term>CB</term>
<def><p>Clark-Baudouin</p></def>
</def-item>
<def-item><term>CI</term>
<def><p>Confidence interval</p></def>
</def-item>
<def-item><term>CID</term>
<def><p>Confidence interval difference</p></def>
</def-item>
<def-item><term>EH</term>
<def><p>Eliminated heterogeneity</p></def>
</def-item>
<def-item><term>ES</term>
<def><p>Elevated significance</p></def>
</def-item>
<def-item><term>F</term>
<def><p>Fixed-effects</p></def>
</def-item>
<def-item><term>GE</term>
<def><p>Gene-environment interaction</p></def>
</def-item>
<def-item><term>GG</term>
<def><p>Gene-gene interaction</p></def>
</def-item>
<def-item><term>GS</term>
<def><p>Gain in significance</p></def>
</def-item>
<def-item><term>GWAS</term>
<def><p>Genome-Wide Association Studies</p></def>
</def-item>
<def-item><term>HC</term>
<def><p>Healthy control</p></def>
</def-item>
<def-item><term>HP</term>
<def><p>Haplotype</p></def>
</def-item>
<def-item><term>HWE</term>
<def><p>Hardy-Weinberg Equilibrium</p></def>
</def-item>
<def-item><term>I<sup>2</sup></term>
<def><p>Measure of inconsistency expressed in %</p></def>
</def-item>
<def-item><term>IQR</term>
<def><p>Interquartile range</p></def>
</def-item>
<def-item><term>K</term>
<def><p>Number designation of the study</p></def>
</def-item>
<def-item><term>KS</term>
<def><p>Kolmogorov-Smirnov test</p></def>
</def-item>
<def-item><term>Log OR</term>
<def><p>Logarithm of OR</p></def>
</def-item>
<def-item><term>M</term>
<def><p>Ma et al</p></def>
</def-item>
<def-item><term>maf</term>
<def><p>Minor allele frequency</p></def>
</def-item>
<def-item><term>MC</term>
<def><p>More in control</p></def>
</def-item>
<def-item><term>MP</term>
<def><p>More in power</p></def>
</def-item>
<def-item><term>n</term>
<def><p>Number of studies</p></def>
</def-item>
<def-item><term>NC</term>
<def><p>No change in heterogeneity</p></def>
</def-item>
<def-item><term>NM</term>
<def><p>No mention</p></def>
</def-item>
<def-item><term>OR</term>
<def><p>Odds ratio</p></def>
</def-item>
<def-item><term>P</term>
<def><p>P-value</p></def>
</def-item>
<def-item><term>P<sup>a</sup></term>
<def><p>P-value for association</p></def>
</def-item>
<def-item><term>P<sup>b</sup></term>
<def><p>P-value for heterogeneity</p></def>
</def-item>
<def-item><term>P<sub>BC</sub></term>
<def><p>Bonferroni-corrected P-value</p></def>
</def-item>
<def-item><term>PRISMA</term>
<def><p>Preferred Reporting Items for Systematic Reviews and Meta-Analyses</p></def>
</def-item>
<def-item><term>PRO</term>
<def><p>Pre-outlier</p></def>
</def-item>
<def-item><term>PS</term>
<def><p>Power sports</p></def>
</def-item>
<def-item><term>PSO</term>
<def><p>Post-outlier</p></def>
</def-item>
<def-item><term>R</term>
<def><p>Wild-type <italic>ACTN3</italic> R577X polymorphism</p></def>
</def-item>
<def-item><term>RE</term>
<def><p>Random-effects</p></def>
</def-item>
<def-item><term>RH</term>
<def><p>Reduced heterogeneity</p></def>
</def-item>
<def-item><term>RNS</term>
<def><p>Retained non-significance</p></def>
</def-item>
<def-item><term>RS</term>
<def><p>Retained significance</p></def>
</def-item>
<def-item><term>RX</term>
<def><p>Heterozygous genotype of <italic>ACTN3</italic> R577X polymorphism</p></def>
</def-item>
<def-item><term>SigMP</term>
<def><p>Significantly more in power</p></def>
</def-item>
<def-item><term>USA</term>
<def><p>United States of America</p></def>
</def-item>
<def-item><term>v</term>
<def><p>versus</p></def>
</def-item>
<def-item><term>W</term>
<def><p>Western</p></def>
</def-item>
<def-item><term>WY</term>
<def><p>Weyerstraß et al</p></def>
</def-item>
<def-item><term>X</term>
<def><p>Variant type <italic>ACTN3</italic> R577X polymorphism</p></def>
</def-item>
<def-item><term>τ<sup>2</sup></term>
<def><p>Tau-square</p></def>
</def-item>
<def-item><term>χ<sup>2</sup></term>
<def><p>Chi-square</p></def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="pone.0217390.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Macarthur</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>North</surname> <given-names>KN</given-names></name> (<year>2005</year>) <article-title>Genes and human elite athletic performance</article-title>. <source>Hum Genet</source> <volume>116</volume>: <fpage>331</fpage>–<lpage>339</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00439-005-1261-8" xlink:type="simple">10.1007/s00439-005-1261-8</ext-link></comment> <object-id pub-id-type="pmid">15726413</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ahmetov</surname> <given-names>II</given-names></name>, <name name-style="western"><surname>Fedotovskaya</surname> <given-names>ON</given-names></name> (<year>2015</year>) <article-title>Current Progress in Sports Genomics</article-title>. <source>Adv Clin Chem</source> <volume>70</volume>: <fpage>247</fpage>–<lpage>314</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/bs.acc.2015.03.003" xlink:type="simple">10.1016/bs.acc.2015.03.003</ext-link></comment> <object-id pub-id-type="pmid">26231489</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Roth</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Rankinen</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Hagberg</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Loos</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Perusse</surname> <given-names>L</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Advances in exercise, fitness, and performance genomics in 2011</article-title>. <source>Med Sci Sports Exerc</source> <volume>44</volume>: <fpage>809</fpage>–<lpage>817</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1249/MSS.0b013e31824f28b6" xlink:type="simple">10.1249/MSS.0b013e31824f28b6</ext-link></comment> <object-id pub-id-type="pmid">22330029</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yang</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>MacArthur</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Gulbin</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Hahn</surname> <given-names>AG</given-names></name>, <name name-style="western"><surname>Beggs</surname> <given-names>AH</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>ACTN3 genotype is associated with human elite athletic performance</article-title>. <source>Am J Hum Genet</source> <volume>73</volume>: <fpage>627</fpage>–<lpage>631</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/377590" xlink:type="simple">10.1086/377590</ext-link></comment> <object-id pub-id-type="pmid">12879365</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eynon</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Ruiz</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Oliveira</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Duarte</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Birk</surname> <given-names>R</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Genes and elite athletes: a roadmap for future research</article-title>. <source>J Physiol</source> <volume>589</volume>: <fpage>3063</fpage>–<lpage>3070</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1113/jphysiol.2011.207035" xlink:type="simple">10.1113/jphysiol.2011.207035</ext-link></comment> <object-id pub-id-type="pmid">21540342</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pitsiladis</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Wolfarth</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Scott</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Fuku</surname> <given-names>N</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Genomics of elite sporting performance: what little we know and necessary advances</article-title>. <source>Br J Sports Med</source> <volume>47</volume>: <fpage>550</fpage>–<lpage>555</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bjsports-2013-092400" xlink:type="simple">10.1136/bjsports-2013-092400</ext-link></comment> <object-id pub-id-type="pmid">23632745</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kikuchi</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Nakazato</surname> <given-names>K</given-names></name> (<year>2015</year>) <article-title>Effective utilization of genetic information for athletes and coaches: focus on ACTN3 R577X polymorphism</article-title>. <source>J Exerc Nutrition Biochem</source> <volume>19</volume>: <fpage>157</fpage>–<lpage>164</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5717/jenb.2015.15093001" xlink:type="simple">10.5717/jenb.2015.15093001</ext-link></comment> <object-id pub-id-type="pmid">26526670</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eynon</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Hanson</surname> <given-names>ED</given-names></name>, <name name-style="western"><surname>Lucia</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Houweling</surname> <given-names>PJ</given-names></name>, <name name-style="western"><surname>Garton</surname> <given-names>F</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Genes for elite power and sprint performance: ACTN3 leads the way</article-title>. <source>Sports Med</source> <volume>43</volume>: <fpage>803</fpage>–<lpage>817</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s40279-013-0059-4" xlink:type="simple">10.1007/s40279-013-0059-4</ext-link></comment> <object-id pub-id-type="pmid">23681449</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>North</surname> <given-names>KN</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Wattanasirichaigoon</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Mills</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Easteal</surname> <given-names>S</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>A common nonsense mutation results in alpha-actinin-3 deficiency in the general population</article-title>. <source>Nat Genet</source> <volume>21</volume>: <fpage>353</fpage>–<lpage>354</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/7675" xlink:type="simple">10.1038/7675</ext-link></comment> <object-id pub-id-type="pmid">10192379</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ma</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Gao</surname> <given-names>C</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>The association of sport performance with ACE and ACTN3 genetic polymorphisms: a systematic review and meta-analysis</article-title>. <source>PLoS One</source> <volume>8</volume>: <fpage>e54685</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0054685" xlink:type="simple">10.1371/journal.pone.0054685</ext-link></comment> <object-id pub-id-type="pmid">23358679</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pereira</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Costa</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Izquierdo</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Silva</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Bastos</surname> <given-names>E</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>ACE I/D and ACTN3 R/X polymorphisms as potential factors in modulating exercise-related phenotypes in older women in response to a muscle power training stimuli</article-title>. <source>Age (Dordr)</source> <volume>35</volume>: <fpage>1949</fpage>–<lpage>1959</lpage>.</mixed-citation></ref>
<ref id="pone.0217390.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Delmonico</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Kostek</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Doldo</surname> <given-names>NA</given-names></name>, <name name-style="western"><surname>Hand</surname> <given-names>BD</given-names></name>, <name name-style="western"><surname>Walsh</surname> <given-names>S</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Alpha-actinin-3 (ACTN3) R577X polymorphism influences knee extensor peak power response to strength training in older men and women</article-title>. <source>J Gerontol A Biol Sci Med Sci</source> <volume>62</volume>: <fpage>206</fpage>–<lpage>212</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/gerona/62.2.206" xlink:type="simple">10.1093/gerona/62.2.206</ext-link></comment> <object-id pub-id-type="pmid">17339648</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alfred</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Ben-Shlomo</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Cooper</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Hardy</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Cooper</surname> <given-names>C</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>ACTN3 genotype, athletic status, and life course physical capability: meta-analysis of the published literature and findings from nine studies</article-title>. <source>Hum Mutat</source> <volume>32</volume>: <fpage>1008</fpage>–<lpage>1018</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/humu.21526" xlink:type="simple">10.1002/humu.21526</ext-link></comment> <object-id pub-id-type="pmid">21542061</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>FX</given-names></name>, <name name-style="western"><surname>Houweling</surname> <given-names>PJ</given-names></name>, <name name-style="western"><surname>North</surname> <given-names>KN</given-names></name>, <name name-style="western"><surname>Quinlan</surname> <given-names>KG</given-names></name> (<year>2016</year>) <article-title>How does alpha-actinin-3 deficiency alter muscle function? Mechanistic insights into ACTN3, the ’gene for speed'</article-title>. <source>Biochim Biophys Acta</source> <volume>1863</volume>: <fpage>686</fpage>–<lpage>693</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bbamcr.2016.01.013" xlink:type="simple">10.1016/j.bbamcr.2016.01.013</ext-link></comment></mixed-citation></ref>
<ref id="pone.0217390.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pickering</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Kiely</surname> <given-names>J</given-names></name> (<year>2017</year>) <article-title>ACTN3: More than Just a Gene for Speed</article-title>. <source>Front Physiol</source> <volume>8</volume>: <fpage>1080</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphys.2017.01080" xlink:type="simple">10.3389/fphys.2017.01080</ext-link></comment> <object-id pub-id-type="pmid">29326606</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egorova</surname> <given-names>ES</given-names></name>, <name name-style="western"><surname>Borisova</surname> <given-names>AV</given-names></name>, <name name-style="western"><surname>Mustafina</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Arkhipova</surname> <given-names>AA</given-names></name>, <name name-style="western"><surname>Gabbasov</surname> <given-names>RT</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>The polygenic profile of Russian football players</article-title>. <source>J Sports Sci</source> <volume>32</volume>: <fpage>1286</fpage>–<lpage>1293</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/02640414.2014.898853" xlink:type="simple">10.1080/02640414.2014.898853</ext-link></comment> <object-id pub-id-type="pmid">24784145</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eynon</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Alves</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Meckel</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Yamin</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Ayalon</surname> <given-names>M</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Is the interaction between HIF1A P582S and ACTN3 R577X determinant for power/sprint performance?</article-title> <source>Metabolism</source> <volume>59</volume>: <fpage>861</fpage>–<lpage>865</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.metabol.2009.10.003" xlink:type="simple">10.1016/j.metabol.2009.10.003</ext-link></comment> <object-id pub-id-type="pmid">20005538</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grenda</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Leonska-Duniec</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kaczmarczyk</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ficek</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Krol</surname> <given-names>P</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>Interaction Between ACE I/D and ACTN3 R557X Polymorphisms in Polish Competitive Swimmers</article-title>. <source>J Hum Kinet</source> <volume>42</volume>: <fpage>127</fpage>–<lpage>136</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2478/hukin-2014-0067" xlink:type="simple">10.2478/hukin-2014-0067</ext-link></comment> <object-id pub-id-type="pmid">25414746</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ruiz</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Arteta</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Buxens</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Artieda</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Gomez-Gallego</surname> <given-names>F</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Can we identify a power-oriented polygenic profile?</article-title> <source>J Appl Physiol (1985)</source> <volume>108</volume>: <fpage>561</fpage>–<lpage>566</lpage>.</mixed-citation></ref>
<ref id="pone.0217390.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Santiago</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Ruiz</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Muniesa</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Gonzalez-Freire</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Gomez-Gallego</surname> <given-names>F</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Does the polygenic profile determine the potential for becoming a world-class athlete? Insights from the sport of rowing</article-title>. <source>Scand J Med Sci Sports</source> <volume>20</volume>: <fpage>e188</fpage>–<lpage>194</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1600-0838.2009.00943.x" xlink:type="simple">10.1111/j.1600-0838.2009.00943.x</ext-link></comment> <object-id pub-id-type="pmid">19422651</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gineviciene</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Jakaitiene</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Aksenov</surname> <given-names>MO</given-names></name>, <name name-style="western"><surname>Aksenova</surname> <given-names>AV</given-names></name>, <name name-style="western"><surname>Druzhevskaya</surname> <given-names>AM</given-names></name>, <etal>et al</etal>. (<year>2016</year>) <article-title>Association analysis of ACE, ACTN3 and PPARGC1A gene polymorphisms in two cohorts of European strength and power athletes</article-title>. <source>Biol Sport</source> <volume>33</volume>: <fpage>199</fpage>–<lpage>206</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5604/20831862.1201051" xlink:type="simple">10.5604/20831862.1201051</ext-link></comment> <object-id pub-id-type="pmid">27601773</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Mikami</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Chiu</surname> <given-names>LL</given-names></name>, <name name-style="western"><surname>A</surname> <given-names>DEP</given-names></name>, <name name-style="western"><surname>Deason</surname> <given-names>M</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Association analysis of ACE and ACTN3 in elite Caucasian and East Asian swimmers</article-title>. <source>Med Sci Sports Exerc</source> <volume>45</volume>: <fpage>892</fpage>–<lpage>900</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1249/MSS.0b013e31827c501f" xlink:type="simple">10.1249/MSS.0b013e31827c501f</ext-link></comment> <object-id pub-id-type="pmid">23190598</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eynon</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Duarte</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Oliveira</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Sagiv</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Yamin</surname> <given-names>C</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>ACTN3 R577X polymorphism and Israeli top-level athletes</article-title>. <source>Int J Sports Med</source> <volume>30</volume>: <fpage>695</fpage>–<lpage>698</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1055/s-0029-1220731" xlink:type="simple">10.1055/s-0029-1220731</ext-link></comment> <object-id pub-id-type="pmid">19544227</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Juffer</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Furrer</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Gonzalez-Freire</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Santiago</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Verde</surname> <given-names>Z</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Genotype distributions in top-level soccer players: a role for ACE?</article-title> <source>Int J Sports Med</source> <volume>30</volume>: <fpage>387</fpage>–<lpage>392</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1055/s-0028-1105931" xlink:type="simple">10.1055/s-0028-1105931</ext-link></comment> <object-id pub-id-type="pmid">19277943</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Garatachea</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Verde</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Santos-Lozano</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Yvert</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Rodriguez-Romo</surname> <given-names>G</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>ACTN3 R577X polymorphism and explosive leg-muscle power in elite basketball players</article-title>. <source>Int J Sports Physiol Perform</source> <volume>9</volume>: <fpage>226</fpage>–<lpage>232</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1123/ijspp.2012-0331" xlink:type="simple">10.1123/ijspp.2012-0331</ext-link></comment> <object-id pub-id-type="pmid">23689106</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Peplonska</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Adamczyk</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Siewierski</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Safranow</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Maruszak</surname> <given-names>A</given-names></name>, <etal>et al</etal>. (<year>2017</year>) <article-title>Genetic variants associated with physical and mental characteristics of the elite athletes in the Polish population</article-title>. <source>Scand J Med Sci Sports</source> <volume>27</volume>: <fpage>788</fpage>–<lpage>800</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/sms.12687" xlink:type="simple">10.1111/sms.12687</ext-link></comment> <object-id pub-id-type="pmid">27140937</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mikami</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Fuku</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Murakami</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Tsuchie</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Takahashi</surname> <given-names>H</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>ACTN3 R577X genotype is associated with sprinting in elite Japanese athletes</article-title>. <source>Int J Sports Med</source> <volume>35</volume>: <fpage>172</fpage>–<lpage>177</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1055/s-0033-1347171" xlink:type="simple">10.1055/s-0033-1347171</ext-link></comment> <object-id pub-id-type="pmid">23868678</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Massidda</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Bachis</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Corrias</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Piras</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Scorcu</surname> <given-names>M</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>ACTN3 R577X polymorphism is not associated with team sport athletic status in Italians</article-title>. <source>Sports Med Open</source> <volume>1</volume>: <fpage>6</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s40798-015-0008-x" xlink:type="simple">10.1186/s40798-015-0008-x</ext-link></comment> <object-id pub-id-type="pmid">27747845</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Papadimitriou</surname> <given-names>ID</given-names></name>, <name name-style="western"><surname>Lockey</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Voisin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Herbert</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Garton</surname> <given-names>F</given-names></name>, <etal>et al</etal>. (<year>2018</year>) <article-title>No association between ACTN3 R577X and ACE I/D polymorphisms and endurance running times in 698 Caucasian athletes</article-title>. <source>BMC Genomics</source> <volume>19</volume>: <fpage>13</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12864-017-4412-0" xlink:type="simple">10.1186/s12864-017-4412-0</ext-link></comment> <object-id pub-id-type="pmid">29298672</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ruiz</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Fernandez del Valle</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Verde</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Diez-Vega</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Santiago</surname> <given-names>C</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>ACTN3 R577X polymorphism does not influence explosive leg muscle power in elite volleyball players</article-title>. <source>Scand J Med Sci Sports</source> <volume>21</volume>: <fpage>e34</fpage>–<lpage>41</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1600-0838.2010.01134.x" xlink:type="simple">10.1111/j.1600-0838.2010.01134.x</ext-link></comment> <object-id pub-id-type="pmid">20561285</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lorenz</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Reiman</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Lehecka</surname> <given-names>BJ</given-names></name>, <name name-style="western"><surname>Naylor</surname> <given-names>A</given-names></name> (<year>2013</year>) <article-title>What performance characteristics determine elite versus nonelite athletes in the same sport?</article-title> <source>Sports Health</source> <volume>5</volume>: <fpage>542</fpage>–<lpage>547</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/1941738113479763" xlink:type="simple">10.1177/1941738113479763</ext-link></comment> <object-id pub-id-type="pmid">24427430</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Clark</surname> <given-names>MF</given-names></name>, <name name-style="western"><surname>Baudouin</surname> <given-names>SV</given-names></name> (<year>2006</year>) <article-title>A systematic review of the quality of genetic association studies in human sepsis</article-title>. <source>Intensive Care Med</source> <volume>32</volume>: <fpage>1706</fpage>–<lpage>1712</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00134-006-0327-y" xlink:type="simple">10.1007/s00134-006-0327-y</ext-link></comment> <object-id pub-id-type="pmid">16957907</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lilliefors</surname> <given-names>HW</given-names></name> (<year>1967</year>) <article-title>On the Kolmogorov-Smirnov Test for Normality with Mean and Variance Unknown</article-title>. <source>J Am Stat Assoc</source> <volume>62</volume> <fpage>399</fpage>–<lpage>402</lpage>.</mixed-citation></ref>
<ref id="pone.0217390.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abramson</surname> <given-names>JH</given-names></name> (<year>2004</year>) <article-title>WINPEPI (PEPI-for-Windows): computer programs for epidemiologists</article-title>. <source>Epidemiol Perspect Innov</source> <volume>1</volume>: <fpage>6</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1742-5573-1-6" xlink:type="simple">10.1186/1742-5573-1-6</ext-link></comment> <object-id pub-id-type="pmid">15606913</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Davey Smith</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname> <given-names>C</given-names></name> (<year>1997</year>) <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>Bmj</source> <volume>315</volume>: <fpage>629</fpage>–<lpage>634</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.315.7109.629" xlink:type="simple">10.1136/bmj.315.7109.629</ext-link></comment> <object-id pub-id-type="pmid">9310563</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name> (<year>1994</year>) <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source> <volume>50</volume>: <fpage>1088</fpage>–<lpage>1101</lpage>. <object-id pub-id-type="pmid">7786990</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref037"><label>37</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>FH</surname> <given-names>V.M. Berthold</given-names></name>, <name name-style="western"><surname>Klawon</surname> <given-names>F.</given-names></name> (<year>2010</year>) <chapter-title>How to intelligently make sense of real data, in descriptive statistics</chapter-title>. In: <collab>Springer</collab>, editor. <source>Guide to Intelligent Data Analysis</source>: <publisher-name>Springer</publisher-name> pp. p. <fpage>315</fpage>.</mixed-citation></ref>
<ref id="pone.0217390.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Higgins</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>SG</given-names></name>, <name name-style="western"><surname>Deeks</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name> (<year>2003</year>) <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>Bmj</source> <volume>327</volume>: <fpage>557</fpage>–<lpage>560</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.327.7414.557" xlink:type="simple">10.1136/bmj.327.7414.557</ext-link></comment> <object-id pub-id-type="pmid">12958120</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lau</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ioannidis</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Schmid</surname> <given-names>CH</given-names></name> (<year>1997</year>) <article-title>Quantitative synthesis in systematic reviews</article-title>. <source>Ann Intern Med</source> <volume>127</volume>: <fpage>820</fpage>–<lpage>826</lpage>. <object-id pub-id-type="pmid">9382404</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Higgins</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>SG</given-names></name> (<year>2002</year>) <article-title>Quantifying heterogeneity in a meta-analysis</article-title>. <source>Stat Med</source> <volume>21</volume>: <fpage>1539</fpage>–<lpage>1558</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/sim.1186" xlink:type="simple">10.1002/sim.1186</ext-link></comment> <object-id pub-id-type="pmid">12111919</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Galbraith</surname> <given-names>R</given-names></name> (<year>1988</year>) <article-title>A note on graphical presentation of estimated odds ratios from several clinical trials</article-title>. <source>Stat Med</source> <volume>7</volume>: <fpage>889</fpage>–<lpage>894</lpage>. <object-id pub-id-type="pmid">3413368</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lohmueller</surname> <given-names>KE</given-names></name>, <name name-style="western"><surname>Pearce</surname> <given-names>CL</given-names></name>, <name name-style="western"><surname>Pike</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lander</surname> <given-names>ES</given-names></name>, <name name-style="western"><surname>Hirschhorn</surname> <given-names>JN</given-names></name> (<year>2003</year>) <article-title>Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease</article-title>. <source>Nat Genet</source> <volume>33</volume>: <fpage>177</fpage>–<lpage>182</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng1071" xlink:type="simple">10.1038/ng1071</ext-link></comment> <object-id pub-id-type="pmid">12524541</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nikolakopoulou</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Mavridis</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Salanti</surname> <given-names>G</given-names></name> (<year>2014</year>) <article-title>Demystifying fixed and random effects meta-analysis</article-title>. <source>Evid Based Ment Health</source> <volume>17</volume>: <fpage>53</fpage>–<lpage>57</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/eb-2014-101795" xlink:type="simple">10.1136/eb-2014-101795</ext-link></comment> <object-id pub-id-type="pmid">24692250</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sedgwick</surname> <given-names>P</given-names></name> (<year>2015</year>) <article-title>Meta-analyses: what is heterogeneity?</article-title> <source>BMJ</source> <volume>350</volume>: <fpage>h1435</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.h1435" xlink:type="simple">10.1136/bmj.h1435</ext-link></comment> <object-id pub-id-type="pmid">25778910</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mantel</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Haenszel</surname> <given-names>W</given-names></name> (<year>1959</year>) <article-title>Statistical aspects of the analysis of data from retrospective studies of disease</article-title>. <source>J Natl Cancer Inst</source> <volume>22</volume>: <fpage>719</fpage>–<lpage>748</lpage>. <object-id pub-id-type="pmid">13655060</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DerSimonian</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Laird</surname> <given-names>N</given-names></name> (<year>1986</year>) <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source> <volume>7</volume>: <fpage>177</fpage>–<lpage>188</lpage>. <object-id pub-id-type="pmid">3802833</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Bland</surname> <given-names>JM</given-names></name> (<year>2003</year>) <article-title>Interaction revisited: the difference between two estimates</article-title>. <source>BMJ</source> <volume>326</volume>: <fpage>219</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.326.7382.219" xlink:type="simple">10.1136/bmj.326.7382.219</ext-link></comment> <object-id pub-id-type="pmid">12543843</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref048"><label>48</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>P</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Miyamoto-Mikami</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Fuku</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Tanaka</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Miyachi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Murakami</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Ching Cheng</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Mitchell</surname> <given-names>BD</given-names></name>, <name name-style="western"><surname>Austin</surname> <given-names>KG</given-names></name>, and <name name-style="western"><surname>Pitsiladis</surname> <given-names>YP</given-names></name> (<year>2014</year>) <chapter-title>GWAS of Elite Jamaican, African American and Japanese Sprint Athletes</chapter-title>. In: <name name-style="western"><surname>M</surname> <given-names>S</given-names></name>, editor. <source>Genetics</source>:: <publisher-name>American College of Sports Medicine</publisher-name>.</mixed-citation></ref>
<ref id="pone.0217390.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weyerstrass</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Stewart</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Wesselius</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Zeegers</surname> <given-names>M</given-names></name> (<year>2018</year>) <article-title>Nine genetic polymorphisms associated with power athlete status—A Meta-Analysis</article-title>. <source>J Sci Med Sport</source> <volume>21</volume>: <fpage>213</fpage>–<lpage>220</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jsams.2017.06.012" xlink:type="simple">10.1016/j.jsams.2017.06.012</ext-link></comment></mixed-citation></ref>
<ref id="pone.0217390.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Garton</surname> <given-names>FC</given-names></name>, <name name-style="western"><surname>Houweling</surname> <given-names>PJ</given-names></name>, <name name-style="western"><surname>Vukcevic</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Meehan</surname> <given-names>LR</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>FXZ</given-names></name>, <etal>et al</etal>. (<year>2018</year>) <article-title>The Effect of ACTN3 Gene Doping on Skeletal Muscle Performance</article-title>. <source>Am J Hum Genet</source> <volume>102</volume>: <fpage>845</fpage>–<lpage>857</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ajhg.2018.03.009" xlink:type="simple">10.1016/j.ajhg.2018.03.009</ext-link></comment> <object-id pub-id-type="pmid">29706347</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gineviciene</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Pranculis</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Jakaitiene</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Milasius</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kucinskas</surname> <given-names>V</given-names></name> (<year>2011</year>) <article-title>Genetic variation of the human ACE and ACTN3 genes and their association with functional muscle properties in Lithuanian elite athletes</article-title>. <source>Medicina (Kaunas)</source> <volume>47</volume>: <fpage>284</fpage>–<lpage>290</lpage>.</mixed-citation></ref>
<ref id="pone.0217390.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Papadimitriou</surname> <given-names>ID</given-names></name>, <name name-style="western"><surname>Papadopoulos</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Kouvatsi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Triantaphyllidis</surname> <given-names>C</given-names></name> (<year>2008</year>) <article-title>The ACTN3 gene in elite Greek track and field athletes</article-title>. <source>Int J Sports Med</source> <volume>29</volume>: <fpage>352</fpage>–<lpage>355</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1055/s-2007-965339" xlink:type="simple">10.1055/s-2007-965339</ext-link></comment> <object-id pub-id-type="pmid">17879893</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Druzhevskaya</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Ahmetov</surname> <given-names>II</given-names></name>, <name name-style="western"><surname>Astratenkova</surname> <given-names>IV</given-names></name>, <name name-style="western"><surname>Rogozkin</surname> <given-names>VA</given-names></name> (<year>2008</year>) <article-title>Association of the ACTN3 R577X polymorphism with power athlete status in Russians</article-title>. <source>Eur J Appl Physiol</source> <volume>103</volume>: <fpage>631</fpage>–<lpage>634</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00421-008-0763-1" xlink:type="simple">10.1007/s00421-008-0763-1</ext-link></comment> <object-id pub-id-type="pmid">18470530</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eynon</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Banting</surname> <given-names>LK</given-names></name>, <name name-style="western"><surname>Ruiz</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Cieszczyk</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Dyatlov</surname> <given-names>DA</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>ACTN3 R577X polymorphism and team-sport performance: a study involving three European cohorts</article-title>. <source>J Sci Med Sport</source> <volume>17</volume>: <fpage>102</fpage>–<lpage>106</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jsams.2013.02.005" xlink:type="simple">10.1016/j.jsams.2013.02.005</ext-link></comment> <object-id pub-id-type="pmid">23522773</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kikuchi</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Ueda</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Min</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Nakazato</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Igawa</surname> <given-names>S</given-names></name> (<year>2013</year>) <article-title>The ACTN3 XX genotype’s underrepresentation in Japanese elite wrestlers</article-title>. <source>Int J Sports Physiol Perform</source> <volume>8</volume>: <fpage>57</fpage>–<lpage>61</lpage>. <object-id pub-id-type="pmid">22868563</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ruiz</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Santiago</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Yvert</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Muniesa</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Diaz-Urena</surname> <given-names>G</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>ACTN3 genotype in Spanish elite swimmers: no "heterozygous advantage"</article-title>. <source>Scand J Med Sci Sports</source> <volume>23</volume>: <fpage>e162</fpage>–<lpage>167</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/sms.12045" xlink:type="simple">10.1111/sms.12045</ext-link></comment> <object-id pub-id-type="pmid">23317015</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref057"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Santiago</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Gonzalez-Freire</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Serratosa</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Morate</surname> <given-names>FJ</given-names></name>, <name name-style="western"><surname>Meyer</surname> <given-names>T</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>ACTN3 genotype in professional soccer players</article-title>. <source>Br J Sports Med</source> <volume>42</volume>: <fpage>71</fpage>–<lpage>73</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bjsm.2007.039172" xlink:type="simple">10.1136/bjsm.2007.039172</ext-link></comment> <object-id pub-id-type="pmid">17550918</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref058"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ioannidis</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Trikalinos</surname> <given-names>TA</given-names></name> (<year>2007</year>) <article-title>The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey</article-title>. <source>CMAJ</source> <volume>176</volume>: <fpage>1091</fpage>–<lpage>1096</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1503/cmaj.060410" xlink:type="simple">10.1503/cmaj.060410</ext-link></comment> <object-id pub-id-type="pmid">17420491</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref059"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vincent</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>De Bock</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Ramaekers</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Van den Eede</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Van Leemputte</surname> <given-names>M</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>ACTN3 (R577X) genotype is associated with fiber type distribution</article-title>. <source>Physiol Genomics</source> <volume>32</volume>: <fpage>58</fpage>–<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1152/physiolgenomics.00173.2007" xlink:type="simple">10.1152/physiolgenomics.00173.2007</ext-link></comment> <object-id pub-id-type="pmid">17848603</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref060"><label>60</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>MacArthur</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Seto</surname> <given-names>JT</given-names></name>, <name name-style="western"><surname>Raftery</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Quinlan</surname> <given-names>KG</given-names></name>, <name name-style="western"><surname>Huttley</surname> <given-names>GA</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Loss of ACTN3 gene function alters mouse muscle metabolism and shows evidence of positive selection in humans</article-title>. <source>Nat Genet</source> <volume>39</volume>: <fpage>1261</fpage>–<lpage>1265</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng2122" xlink:type="simple">10.1038/ng2122</ext-link></comment> <object-id pub-id-type="pmid">17828264</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref061"><label>61</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Broos</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Van Leemputte</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Deldicque</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Thomis</surname> <given-names>MA</given-names></name> (<year>2015</year>) <article-title>History-dependent force, angular velocity and muscular endurance in ACTN3 genotypes</article-title>. <source>Eur J Appl Physiol</source> <volume>115</volume>: <fpage>1637</fpage>–<lpage>1643</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00421-015-3144-6" xlink:type="simple">10.1007/s00421-015-3144-6</ext-link></comment> <object-id pub-id-type="pmid">25761730</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref062"><label>62</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Walsh</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Metter</surname> <given-names>EJ</given-names></name>, <name name-style="western"><surname>Ferrucci</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Roth</surname> <given-names>SM</given-names></name> (<year>2008</year>) <article-title>ACTN3 genotype is associated with muscle phenotypes in women across the adult age span</article-title>. <source>J Appl Physiol (1985)</source> <volume>105</volume>: <fpage>1486</fpage>–<lpage>1491</lpage>.</mixed-citation></ref>
<ref id="pone.0217390.ref063"><label>63</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moran</surname> <given-names>CN</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Bailey</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Tsiokanos</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Jamurtas</surname> <given-names>A</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Association analysis of the ACTN3 R577X polymorphism and complex quantitative body composition and performance phenotypes in adolescent Greeks</article-title>. <source>Eur J Hum Genet</source> <volume>15</volume>: <fpage>88</fpage>–<lpage>93</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.ejhg.5201724" xlink:type="simple">10.1038/sj.ejhg.5201724</ext-link></comment> <object-id pub-id-type="pmid">17033684</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref064"><label>64</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ahmetov</surname> <given-names>II</given-names></name>, <name name-style="western"><surname>Druzhevskaya</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Lyubaeva</surname> <given-names>EV</given-names></name>, <name name-style="western"><surname>Popov</surname> <given-names>DV</given-names></name>, <name name-style="western"><surname>Vinogradova</surname> <given-names>OL</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>The dependence of preferred competitive racing distance on muscle fibre type composition and ACTN3 genotype in speed skaters</article-title>. <source>Exp Physiol</source> <volume>96</volume>: <fpage>1302</fpage>–<lpage>1310</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1113/expphysiol.2011.060293" xlink:type="simple">10.1113/expphysiol.2011.060293</ext-link></comment> <object-id pub-id-type="pmid">21930675</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref065"><label>65</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eynon</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Banting</surname> <given-names>LK</given-names></name>, <name name-style="western"><surname>Ruiz</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Cieszczyk</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Dyatlov</surname> <given-names>DA</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>ACTN3 R577X polymorphism and team-sport performance: a study involving three European cohorts</article-title>. <source>J Sci Med Sport</source> <volume>17</volume>: <fpage>102</fpage>–<lpage>106</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jsams.2013.02.005" xlink:type="simple">10.1016/j.jsams.2013.02.005</ext-link></comment> <object-id pub-id-type="pmid">23522773</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref066"><label>66</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hanson</surname> <given-names>ED</given-names></name>, <name name-style="western"><surname>Ludlow</surname> <given-names>AT</given-names></name>, <name name-style="western"><surname>Sheaff</surname> <given-names>AK</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Roth</surname> <given-names>SM</given-names></name> (<year>2010</year>) <article-title>ACTN3 genotype does not influence muscle power</article-title>. <source>Int J Sports Med</source> <volume>31</volume>: <fpage>834</fpage>–<lpage>838</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1055/s-0030-1263116" xlink:type="simple">10.1055/s-0030-1263116</ext-link></comment> <object-id pub-id-type="pmid">20830656</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref067"><label>67</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Norman</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Esbjornsson</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Rundqvist</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Osterlund</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>von Walden</surname> <given-names>F</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Strength, power, fiber types, and mRNA expression in trained men and women with different ACTN3 R577X genotypes</article-title>. <source>J Appl Physiol (1985)</source> <volume>106</volume>: <fpage>959</fpage>–<lpage>965</lpage>.</mixed-citation></ref>
<ref id="pone.0217390.ref068"><label>68</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Santiago</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Rodriguez-Romo</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Gomez-Gallego</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Gonzalez-Freire</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Yvert</surname> <given-names>T</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Is there an association between ACTN3 R577X polymorphism and muscle power phenotypes in young, non-athletic adults?</article-title> <source>Scand J Med Sci Sports</source> <volume>20</volume>: <fpage>771</fpage>–<lpage>778</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1600-0838.2009.01017.x" xlink:type="simple">10.1111/j.1600-0838.2009.01017.x</ext-link></comment> <object-id pub-id-type="pmid">19807896</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref069"><label>69</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Berman</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>North</surname> <given-names>KN</given-names></name> (<year>2010</year>) <article-title>A gene for speed: the emerging role of alpha-actinin-3 in muscle metabolism</article-title>. <source>Physiology (Bethesda)</source> <volume>25</volume>: <fpage>250</fpage>–<lpage>259</lpage>.</mixed-citation></ref>
<ref id="pone.0217390.ref070"><label>70</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yang</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Shen</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Voisin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Cai</surname> <given-names>G</given-names></name>, <etal>et al</etal>. (<year>2017</year>) <article-title>ACTN3 R577X Gene Variant Is Associated With Muscle-Related Phenotypes in Elite Chinese Sprint/Power Athletes</article-title>. <source>J Strength Cond Res</source> <volume>31</volume>: <fpage>1107</fpage>–<lpage>1115</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1519/JSC.0000000000001558" xlink:type="simple">10.1519/JSC.0000000000001558</ext-link></comment> <object-id pub-id-type="pmid">27442335</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref071"><label>71</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kothari</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Chheda</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Chawla</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Chatterjee</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Chaudhry</surname> <given-names>SK</given-names></name> and <name name-style="western"><surname>Das</surname> <given-names>BR</given-names></name> (<year>2011</year>) <article-title>ACTN3 R577X Polymorphism in Asian Indian Athletes</article-title>. <source>Int J Hum Genet</source> <volume>11</volume>: <fpage>149</fpage>–<lpage>153</lpage>.</mixed-citation></ref>
<ref id="pone.0217390.ref072"><label>72</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eynon</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Ruiz</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Femia</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Pushkarev</surname> <given-names>VP</given-names></name>, <name name-style="western"><surname>Cieszczyk</surname> <given-names>P</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>The ACTN3 R577X polymorphism across three groups of elite male European athletes</article-title>. <source>PLoS One</source> <volume>7</volume>: <fpage>e43132</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0043132" xlink:type="simple">10.1371/journal.pone.0043132</ext-link></comment> <object-id pub-id-type="pmid">22916217</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref073"><label>73</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McCauley</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Mastana</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Hossack</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Macdonald</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Folland</surname> <given-names>JP</given-names></name> (<year>2009</year>) <article-title>Human angiotensin-converting enzyme I/D and alpha-actinin 3 R577X genotypes and muscle functional and contractile properties</article-title>. <source>Exp Physiol</source> <volume>94</volume>: <fpage>81</fpage>–<lpage>89</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1113/expphysiol.2008.043075" xlink:type="simple">10.1113/expphysiol.2008.043075</ext-link></comment> <object-id pub-id-type="pmid">18676575</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref074"><label>74</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chan</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Seto</surname> <given-names>JT</given-names></name>, <name name-style="western"><surname>MacArthur</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>North</surname> <given-names>KN</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>A gene for speed: contractile properties of isolated whole EDL muscle from an alpha-actinin-3 knockout mouse</article-title>. <source>Am J Physiol Cell Physiol</source> <volume>295</volume>: <fpage>C897</fpage>–<lpage>904</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1152/ajpcell.00179.2008" xlink:type="simple">10.1152/ajpcell.00179.2008</ext-link></comment> <object-id pub-id-type="pmid">18650267</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref075"><label>75</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jacques</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Eynon</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Hanson</surname> <given-names>ED</given-names></name> (<year>2019</year>) <article-title>Genetics and Sprint, Strength, and Power Performance: Candidate Gene Versus Genome-Wide Association Study Approaches</article-title>. <source>Nutrition and Enhanced Sports Performance: Elsevier</source>.</mixed-citation></ref>
<ref id="pone.0217390.ref076"><label>76</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bouchard</surname> <given-names>C</given-names></name> (<year>2015</year>) <article-title>Exercise genomics--a paradigm shift is needed: a commentary</article-title>. <source>Br J Sports Med</source> <volume>49</volume>: <fpage>1492</fpage>–<lpage>1496</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bjsports-2015-095294" xlink:type="simple">10.1136/bjsports-2015-095294</ext-link></comment></mixed-citation></ref>
<ref id="pone.0217390.ref077"><label>77</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Tanaka</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Eynon</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>North</surname> <given-names>KN</given-names></name>, <name name-style="western"><surname>Williams</surname> <given-names>AG</given-names></name>, <etal>et al</etal>. <article-title>(2016) The Future of Genomic Research in Athletic Performance and Adaptation to Training</article-title>. <source>Med Sport Sci</source> <volume>61</volume>: <fpage>55</fpage>–<lpage>67</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1159/000445241" xlink:type="simple">10.1159/000445241</ext-link></comment></mixed-citation></ref>
<ref id="pone.0217390.ref078"><label>78</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Delmonico</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Zmuda</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Taylor</surname> <given-names>BC</given-names></name>, <name name-style="western"><surname>Cauley</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Harris</surname> <given-names>TB</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Association of the ACTN3 genotype and physical functioning with age in older adults</article-title>. <source>J Gerontol A Biol Sci Med Sci</source> <volume>63</volume>: <fpage>1227</fpage>–<lpage>1234</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/gerona/63.11.1227" xlink:type="simple">10.1093/gerona/63.11.1227</ext-link></comment> <object-id pub-id-type="pmid">19038838</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref079"><label>79</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Roth</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Ferrell</surname> <given-names>RF</given-names></name>, <name name-style="western"><surname>Hurley</surname> <given-names>BF</given-names></name> (<year>2000</year>) <article-title>Strength training for the prevention and treatment of sarcopenia</article-title>. <source>J Nutr Health Aging</source> <volume>4</volume>: <fpage>143</fpage>–<lpage>155</lpage>. <object-id pub-id-type="pmid">10936901</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref080"><label>80</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pickering</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Kiely</surname> <given-names>J</given-names></name> (<year>2018</year>) <article-title>ACTN3, Morbidity, and Healthy Aging</article-title>. <source>Front Genet</source> <volume>9</volume>: <fpage>15</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fgene.2018.00015" xlink:type="simple">10.3389/fgene.2018.00015</ext-link></comment> <object-id pub-id-type="pmid">29416549</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref081"><label>81</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fuku</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Alis</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Yvert</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Zempo</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Naito</surname> <given-names>H</given-names></name>, <etal>et al</etal>. (<year>2016</year>) <article-title>Muscle-Related Polymorphisms (MSTN rs1805086 and ACTN3 rs1815739) Are Not Associated with Exceptional Longevity in Japanese Centenarians</article-title>. <source>PLoS One</source> <volume>11</volume>: <fpage>e0166605</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0166605" xlink:type="simple">10.1371/journal.pone.0166605</ext-link></comment> <object-id pub-id-type="pmid">27861536</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref082"><label>82</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Garatachea</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Lucia</surname> <given-names>A</given-names></name> (<year>2013</year>) <article-title>Genes and the ageing muscle: a review on genetic association studies</article-title>. <source>Age (Dordr)</source> <volume>35</volume>: <fpage>207</fpage>–<lpage>233</lpage>.</mixed-citation></ref>
<ref id="pone.0217390.ref083"><label>83</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>North</surname> <given-names>K</given-names></name> (<year>2008</year>) <article-title>Why is alpha-actinin-3 deficiency so common in the general population? The evolution of athletic performance</article-title>. <source>Twin Res Hum Genet</source> <volume>11</volume>: <fpage>384</fpage>–<lpage>394</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1375/twin.11.4.384" xlink:type="simple">10.1375/twin.11.4.384</ext-link></comment> <object-id pub-id-type="pmid">18637739</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref084"><label>84</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Garatachea</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Fiuza-Luces</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Torres-Luque</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Yvert</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Santiago</surname> <given-names>C</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Single and combined influence of ACE and ACTN3 genotypes on muscle phenotypes in octogenarians</article-title>. <source>Eur J Appl Physiol</source> <volume>112</volume>: <fpage>2409</fpage>–<lpage>2420</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00421-011-2217-4" xlink:type="simple">10.1007/s00421-011-2217-4</ext-link></comment> <object-id pub-id-type="pmid">22045415</object-id></mixed-citation></ref>
<ref id="pone.0217390.ref085"><label>85</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Thakkinstian</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>McElduff</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>D’Este</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Duffy</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Attia</surname> <given-names>J</given-names></name> (<year>2005</year>) <article-title>A method for meta-analysis of molecular association studies</article-title>. <source>Stat Med</source> <volume>24</volume>: <fpage>1291</fpage>–<lpage>1306</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/sim.2010" xlink:type="simple">10.1002/sim.2010</ext-link></comment> <object-id pub-id-type="pmid">15568190</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>